<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">cancers</journal-id>
<journal-title-group>
<journal-title>Cancers</journal-title>
</journal-title-group>
<issn pub-type="epub">2072-6694</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31454965</article-id>
<article-id pub-id-type="pmc">6770588</article-id>
<article-id pub-id-type="doi">10.3390/cancers11091247</article-id>
<article-id pub-id-type="publisher-id">cancers-11-01247</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Multifaceted Regulation of PTEN Subcellular Distributions and Biological Functions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Tian</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-11-01247">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yiwei</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-11-01247">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9682-0449</contrib-id>
<name>
<surname>Wang</surname>
<given-names>Yubing</given-names>
</name>
<xref ref-type="aff" rid="af2-cancers-11-01247">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Andrew M.</given-names>
</name>
<xref ref-type="aff" rid="af1-cancers-11-01247">1</xref>
<xref ref-type="corresp" rid="c1-cancers-11-01247">*</xref>
</contrib>
</contrib-group>
<aff id="af1-cancers-11-01247"><label>1</label>School of Biomedical Sciences, Room 705, Lo Kwee-Seong Integrated Biomedical Sciences Building, The Chinese University of Hong Kong, Hong Kong SAR, China</aff>
<aff id="af2-cancers-11-01247"><label>2</label>School of Bioscience and Technology, Weifang Medical University, Weifang 261053, China</aff>
<author-notes>
<corresp id="c1-cancers-11-01247"><label>*</label>Correspondence: <email>andrewmchan@cuhk.edu.hk</email>; Tel.: +852-39433771; Fax: +852-26035123</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>9</month>
<year>2019</year>
</pub-date>
<volume>11</volume>
<issue>9</issue>
<elocation-id>1247</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Phosphatase and tensin homolog deleted on chromosome 10 (<italic>PTEN</italic>) is a tumor suppressor gene frequently found to be inactivated in over 30% of human cancers. <italic>PTEN</italic> encodes a 54-kDa lipid phosphatase that serves as a gatekeeper of the phosphoinositide 3-kinase pathway involved in the promotion of multiple pro-tumorigenic phenotypes. Although the PTEN protein plays a pivotal role in carcinogenesis, cumulative evidence has implicated it as a key signaling molecule in several other diseases as well, such as diabetes, Alzheimer’s disease, and autism spectrum disorders. This finding suggests that diverse cell types, especially differentiated cells, express PTEN. At the cellular level, PTEN is widely distributed in all subcellular compartments and organelles. Surprisingly, the cytoplasmic compartment, not the plasma membrane, is the predominant subcellular location of PTEN. More recently, the finding of a secreted ‘long’ isoform of PTEN and the presence of PTEN in the cell nucleus further revealed unexpected biological functions of this multifaceted molecule. At the regulatory level, PTEN activity, stability, and subcellular distribution are modulated by a fascinating array of post-translational modification events, including phosphorylation, ubiquitination, and sumoylation. Dysregulation of these regulatory mechanisms has been observed in various human diseases. In this review, we provide an up-to-date overview of the knowledge gained in the last decade on how different functional domains of PTEN regulate its biological functions, with special emphasis on its subcellular distribution. This review also highlights the findings of published studies that have reported how mutational alterations in specific PTEN domains can lead to pathogenesis in humans. </p>
</abstract>
<kwd-group>
<kwd>PTEN</kwd>
<kwd>PI3K</kwd>
<kwd>phosphatase</kwd>
<kwd>regulation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-cancers-11-01247" sec-type="intro">
<title>1. Introduction </title>
<p>Phosphatase and <italic>TEN</italic>sin homolog deleted on chromosome 10 (<italic>PTEN</italic>) was originally discovered as a bona fide tumor suppressor gene on human chromosome 10q23.3, a region frequently lost in prostate cancer and glioblastoma multiforme [<xref ref-type="bibr" rid="B1-cancers-11-01247">1</xref>,<xref ref-type="bibr" rid="B2-cancers-11-01247">2</xref>,<xref ref-type="bibr" rid="B3-cancers-11-01247">3</xref>]. In the subsequent decades, intensive surveys on <italic>PTEN</italic> mutations in human cancers have revealed widespread genetic and epigenetic inactivation of this gene. The rate of point mutations varies between different tumor types, being as high as 37% in human endometrial cancer [<xref ref-type="bibr" rid="B4-cancers-11-01247">4</xref>,<xref ref-type="bibr" rid="B5-cancers-11-01247">5</xref>]. Loss of heterozygosity is frequently responsible for the complete inactivation of a tumor suppressor gene (<italic>NF1</italic> or <italic>TP53</italic>). <italic>PTEN</italic> is unique in the respect that the loss of its single allele can lead to carcinogenesis. This haploinsufficiency of the <italic>PTEN</italic> gene has been shown to promote prostate cancer [<xref ref-type="bibr" rid="B6-cancers-11-01247">6</xref>,<xref ref-type="bibr" rid="B7-cancers-11-01247">7</xref>]. Furthermore, the <italic>PTEN</italic> gene expression is subject to modulation by a host of noncoding RNAs (ncRNAs) in various human cancers [<xref ref-type="bibr" rid="B8-cancers-11-01247">8</xref>]. These ncRNAs include more than a dozen microRNAs (miRNAs) and long ncRNAs. Dysregulated interactions between miRNAs and competing endogenous RNAs that share similar miRNA response elements can lead to reduced PTEN expression and promote tumor progression [<xref ref-type="bibr" rid="B9-cancers-11-01247">9</xref>].</p>
<p>Inactivation of PTEN’s biochemical function appears to be the major mechanism underlying cancer pathogenesis. PTEN is a dual-specificity lipid and protein phosphatase. It mediates the dephosphorylation of the 3′ phosphate of phosphatidylinositol 3,4,5-triphosphate (PIP3) to phosphatidylinositol 4,5-bisphosphate (PIP2) [<xref ref-type="bibr" rid="B10-cancers-11-01247">10</xref>] and dephosphorylates itself at threonine 366 (T366), thereby unmasking its ability to inhibit cell invasion [<xref ref-type="bibr" rid="B11-cancers-11-01247">11</xref>]. Numerous signaling molecules have been shown to physically interact with PTEN (<xref ref-type="fig" rid="cancers-11-01247-f001">Figure 1</xref>). Proteins that are known to be the direct substrates of PTEN include PTK6, UBB, AKT1, PLK1, RAB7, IKBKB, IRS1, and CREB1 [<xref ref-type="bibr" rid="B12-cancers-11-01247">12</xref>]. Overall, PTEN plays a pivotal role as a gatekeeper of the phosphoinositide 3-kinase (PI3K) pathway and represses downstream signaling events that control cell proliferation, cell survival, and protein synthesis [<xref ref-type="bibr" rid="B13-cancers-11-01247">13</xref>].</p>
<p>The partial crystal structure of PTEN resolved previously has revealed the signature motif HCXXGXXR in its catalytic pocket [<xref ref-type="bibr" rid="B14-cancers-11-01247">14</xref>]. The pocket size is larger than that of conventional protein phosphatases, presumably required for accommodating the larger PIP3 substrate. The C-terminal half of PTEN possesses a C2 domain responsible for phospholipid binding and critical for membrane targeting [<xref ref-type="bibr" rid="B15-cancers-11-01247">15</xref>]. The tail region of ~90 amino acids is referred to as the PEST domain that is rich in negatively charged amino acid residues [<xref ref-type="bibr" rid="B16-cancers-11-01247">16</xref>]. The protein then terminates in a four-amino acid protein–protein interaction domain called the PDZ-binding motif (PDZ-BM) [<xref ref-type="bibr" rid="B17-cancers-11-01247">17</xref>,<xref ref-type="bibr" rid="B18-cancers-11-01247">18</xref>].</p>
<p>At the evolutionary level, PTEN is a unique protein as it is not closely related to other lipid or protein phosphatases. Orthologs of human <italic>PTEN</italic> gene have been reported in evolutionarily distant organisms, including zebrafish, <italic>Drosophila melanogaster</italic>, <italic>Caenorhabditis elegans</italic>, and <italic>Saccharomyces pombe</italic> (<xref ref-type="fig" rid="cancers-11-01247-f002">Figure 2</xref>). The human PTEN protein has sequence similarity with the human Tensin that encodes a focal adhesion protein linking actin filaments and integrins and the auxilin gene that encodes a C2 domain containing protein tyrosine phosphatase-like molecule [<xref ref-type="bibr" rid="B12-cancers-11-01247">12</xref>,<xref ref-type="bibr" rid="B14-cancers-11-01247">14</xref>]. Interestingly, all three members of the tensin family—namely, tensin 1, 2, and 3—possess a protein tyrosine phosphatase domain, albeit inactive, in their N-terminus [<xref ref-type="bibr" rid="B19-cancers-11-01247">19</xref>]. It is believed that PTEN belongs to a class of molecules containing the protein tyrosine phosphatase (PTP)-C2 superdomain that was formed prior to the fungi, plant, and animal kingdom divergence [<xref ref-type="bibr" rid="B19-cancers-11-01247">19</xref>]. This review article will provide an up-to-date overview of the functional domains of PTEN involved in the regulation of its biochemical and biological functions with special emphasis on its role in different subcellular compartments.</p>
</sec>
<sec id="sec2-cancers-11-01247">
<title>2. Domains of PTEN</title>
<sec id="sec2dot1-cancers-11-01247">
<title>2.1. N-Terminal Domain</title>
<p>The 1209-bp coding region of PTEN encodes a 403-amino acid protein with a predicted molecular mass of ~47 kDa. The primary amino acid sequence of PTEN encodes a bipartite molecule and is flanked by flexible protease-sensitive sequences in the amino (N)- and carboxyl (C)-termini. The N-terminal 32-amino acid region is unstructured and possesses three overlapping motifs with distinct biological functions. First, a 10-amino acid PIP2-binding motif (PBM) encompassing residue 6 to 15 that binds either PI(4,5)P2 or PI(5)P to allosterically stimulate the intrinsic lipid phosphatase activity toward PIP3 [<xref ref-type="bibr" rid="B10-cancers-11-01247">10</xref>,<xref ref-type="bibr" rid="B20-cancers-11-01247">20</xref>]. Three basic residues at K13, K14, and R15 are critical for PTEN activation and are mutated in multiple human tumors (<xref ref-type="fig" rid="cancers-11-01247-f003">Figure 3</xref>) [<xref ref-type="bibr" rid="B21-cancers-11-01247">21</xref>]. Second, a nuclear localization sequence of monopartite type between residues 7 and 31, which is characterized by a stretch of basic residues from 13 to 15 (RNKRR). Interestingly, the K13 residue has been shown to undergo both mono- and polyubiquitination [<xref ref-type="bibr" rid="B22-cancers-11-01247">22</xref>]. However, the sequence in the vicinity of K13 does not possess the classical consensus sequence Ψ-K-x-E, where Ψ is a large hydrophobic residue, K is the lysine residue being modified, X is any amino acid, and E is glutamate residue [<xref ref-type="bibr" rid="B23-cancers-11-01247">23</xref>]. In fact, most online ubiquitination site prediction software failed to register a high score for K13. Nevertheless, K13 has been demonstrated to be ubiquitinated in in vivo assays and has been shown to be responsible for PTEN nuclear import [<xref ref-type="bibr" rid="B22-cancers-11-01247">22</xref>]. In addition, a short stretch of sequence from residue 19 to 25 enriched in negatively charged amino acids (DGFDLDL) has been shown to mediate cytoplasmic localization [<xref ref-type="bibr" rid="B24-cancers-11-01247">24</xref>].</p>
</sec>
<sec id="sec2dot2-cancers-11-01247">
<title>2.2. Catalytic Domain</title>
<p>The N-terminal 179-amino acid region from residue 7 to 185 was originally found to display sequence similarity with the dual-specificity phosphatase (DSP), vaccinia virus VH1-related phosphatase, and the PTP1B [<xref ref-type="bibr" rid="B14-cancers-11-01247">14</xref>]. A search in the BLAST protein database revealed transmembrane phosphatase with tensin homology, TPTE, demonstrating the highest level of protein sequence similarities [<xref ref-type="bibr" rid="B25-cancers-11-01247">25</xref>]. Similar to other DSPs and PTPs, PTEN harbors a HCXXGXXR signature motif between residues 123 and 130, which is referred to as the P loop located at the bottom region of the active site. Residues C124 and R130 are essential for catalysis, whereas H123 and G127 are critical for the P loop conformation. Mutations are frequently identified in this region [<xref ref-type="bibr" rid="B4-cancers-11-01247">4</xref>] (<xref ref-type="fig" rid="cancers-11-01247-f003">Figure 3</xref>). In addition, the D92 residue in the “WPD” loop serves as a general acid to mediate the protonation of the leaving oxygen group. However, there are several structural distinctions. First, the active site pocket in PTEN is ~5 × 11 Å wide, which is two times wider than that of PTPB1, although they have a similar depth of ~8 Å. Second, there is an 11-amino acid insertion between residues 42 and 52 and a 4-amino acid insertion between residues 163 and 166. The latter insertion is referred to as the “TI” loop (because of the conserved threonine and isoleucine residues), and this rigid structure has been suggested to cause the extension of the active site in PTEN [<xref ref-type="bibr" rid="B14-cancers-11-01247">14</xref>]. The wider and deeper opening of the active site in PTEN allows accessibility for PIP3, phosphoserine, phosphothreonine, and phosphotyrosine substrates, which reflects the biological versatility of PTEN. Indeed, the G129E mutation found in human tumors highlight the structural determinant of lipid versus protein substrate specificity. G129 is located at the bottom of the active site. The mutation of the glycine residue to glutamate impedes PIP3 access but without affecting protein substrate binding. Thus, G129E mutant is lipid phosphatase dead but protein phosphatase competent [<xref ref-type="bibr" rid="B26-cancers-11-01247">26</xref>]. Interestingly, mutagenesis analysis revealed a PTEN Y138L mutant with preserved lipid phosphatase activity but abolished protein phosphatase activity [<xref ref-type="bibr" rid="B27-cancers-11-01247">27</xref>]. Thus, PTEN is unique in having dual substrate specificity primarily because of its unique primary coding sequences.</p>
</sec>
<sec id="sec2dot3-cancers-11-01247">
<title>2.3. C2 Domain</title>
<p>The C-terminal 166-amino acid region from residue 186 to 351 exhibits structural topology similar to that of the C2 domains of protein kinase Cδ (PKCδ), phospholipase C δ1 (PLCδ1), and phospholipase A2 (cPLA2) [<xref ref-type="bibr" rid="B28-cancers-11-01247">28</xref>]. The overall structure comprises two antiparallel β sheets with two short α helices positioned between the two strands [<xref ref-type="bibr" rid="B14-cancers-11-01247">14</xref>]. The ability of both PLCδ1 and cPLA2 to bind calcium (Ca<sup>2+</sup>) through their three Ca<sup>2+</sup>-binding loops—namely, Ca<sup>2+</sup>-binding region 1 (CBR1), CBR2, and CBR3—induces a change in the electrical potential that modulates lipid-binding affinity [<xref ref-type="bibr" rid="B29-cancers-11-01247">29</xref>]. However, the C2 domain of PTEN lacks all but one of the Ca<sup>2+</sup>-binding motifs and is predicted to not bind Ca<sup>2+</sup>. Instead, the C2 domain of PTEN has a CBR3 loop between residues 259 and 268, and it possesses five positively charged residues at K260, K263, K266, K267, and K269, which interface with the negatively charged groups of phospholipids on the plasma membrane. Furthermore, the CBR3 loop is positioned perpendicularly to the membrane interphase. The presence of two hydrophobic residues at M264 and L265 near the tip of the CBR3 loop is believed to mediate membrane insertion and anchoring of PTEN to the lipid bilayer. Using POPC/POPS anionic vesicles, the C2 domain alone binds with 30 times weaker affinity than the full-length molecule, suggesting that the N-terminal phosphatase domain, not the C2 domain, is critical for driving membrane recruitment [<xref ref-type="bibr" rid="B15-cancers-11-01247">15</xref>]. In addition, PTEN does not have a high affinity toward the nuclear membrane [<xref ref-type="bibr" rid="B15-cancers-11-01247">15</xref>].</p>
</sec>
<sec id="sec2dot4-cancers-11-01247">
<title>2.4. Tail Region</title>
<p>The C-terminal 52-amino acid region between residues 352 and 403 constitutes the tail region of PTEN. It comprises two regulatory motifs: the PEST domain and the PDZ-BM [<xref ref-type="bibr" rid="B14-cancers-11-01247">14</xref>]. This tail region is unstructured, and its flexible nature confers auto-inhibitory properties. The PEST domain constitutes the region from amino acid 352 to 399, which is rich in acidic (aspartate and glutamate) as well as serine and threonine residues. In contrast to the PEST domains in other signaling molecules, which normally promote protein degradation, the PEST domain of PTEN is associated with enhanced protein stability as its deletion has been shown to drastically decrease the PTEN protein expression. The C-tail region of PTEN is also populated by seven serine/threonine residues known to be phosphorylated by several key signaling molecules. These molecules include casein kinase II (CKII) that mediates phosphorylation at S370, S380, T382, T383, and S385; glycogen synthase kinase 3 beta (GSK-3β) that mediates phosphorylation at S362 and T366; and polo-like kinase 3 that mediates phosphorylation at T366 and S370 [<xref ref-type="bibr" rid="B30-cancers-11-01247">30</xref>]. Among these phosphorylation sites, T366 appears to be an auto-dephosphorylation site, and its phosphorylation plays a role in tumor invasion [<xref ref-type="bibr" rid="B11-cancers-11-01247">11</xref>].</p>
</sec>
<sec id="sec2dot5-cancers-11-01247">
<title>2.5. PDZ-BM</title>
<p>The penultimate four amino acids of PTEN, namely ITKV, from residue 400 to 403 constitute the PDZ-BM, which is a short protein–protein interaction sequence that mediates the binding of PTEN to the PDZ domain containing signaling molecules frequently localized to the cell–cell junctions. PDZ domains are categorized into three classes. PTEN PDZ-BM has a shared consensus sequence, S/T-X-Φ-COOH, where X is any amino acid and Φ is any hydrophobic residues, with peptide ligands that bind to class I PDZ domains [<xref ref-type="bibr" rid="B31-cancers-11-01247">31</xref>,<xref ref-type="bibr" rid="B32-cancers-11-01247">32</xref>]. Physiological functions normally ascribed to PDZ domain proteins are mostly dynamic and transient in nature, such as synaptic transmission [<xref ref-type="bibr" rid="B33-cancers-11-01247">33</xref>]. In total, 12 proteins are known to interact with PTEN through its PDZ-BM, namely hDLG, hMAST205, MAGI3, MAGI2, MAGI1, Bazooka/PAR-3, NHERF/EBP50, MPZ-1, PSD95, MAST2, PTPN13, and KIN-4. PTEN PDZ-BM is evolutionarily conserved, with similar sequences found in zebrafish, sea urchin, and <italic>D. melanogaster</italic>. NMR spectroscopy analysis of the binding between PTEN and MAST2-PDZ has revealed that although the last three amino acids of PTEN PDZ-BM, namely TKV, can account for 86% of the binding affinity, the phenylalanine residue at 392 can form hydrophobic interactions with residues in the β2, β3, and β5 strands of MAST2-PDZ [<xref ref-type="bibr" rid="B34-cancers-11-01247">34</xref>]. Thus, these results indicate that PTEN PDZ-BM binds to the PDZ domain primarily through the C-terminal canonical motif, but also uses some distal N-terminal sequences.</p>
</sec>
</sec>
<sec id="sec3-cancers-11-01247">
<title>3. Subcellular Distribution of PTEN</title>
<p>The Human Protein Atlas database (<uri xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</uri>) reveals ubiquitous expression of PTEN in different organs (<xref ref-type="fig" rid="cancers-11-01247-f004">Figure 4</xref>). PTEN was previously believed to be localized in the cytoplasm. However, recent studies have shown that PTEN is also present in various subcellular compartments, such as the nucleus and mitochondria, and can even be secreted into the extracellular environment.</p>
<sec id="sec3dot1-cancers-11-01247">
<title>3.1. Cytoplasmic PTEN</title>
<p>Cytoplasmic PTEN converts PIP3 to PIP2, thus antagonizing PI3K/AKT pathway activation. Under normal conditions, only a small fraction of PTEN dynamically interacts with the plasma membrane [<xref ref-type="bibr" rid="B35-cancers-11-01247">35</xref>]. PTEN can be activated and recruited from the cytoplasm to the inner face of the plasma membrane under some biological conditions to exert its anti-proliferative functions [<xref ref-type="bibr" rid="B15-cancers-11-01247">15</xref>,<xref ref-type="bibr" rid="B35-cancers-11-01247">35</xref>]. Cytoplasmic PTEN also plays an important role in facilitating apoptosis. Several mechanisms have been proposed. As a lipid phosphatase, cytoplasmic PTEN mainly suppresses the activation of the pro-survival kinase AKT, thus promoting the activation of a spectrum of pro-apoptotic genes such as GSK-3β, forkhead box O3a (FOXO3a), and caspase-9 [<xref ref-type="bibr" rid="B36-cancers-11-01247">36</xref>,<xref ref-type="bibr" rid="B37-cancers-11-01247">37</xref>]. Indeed, a positive correlation has been shown to exist between cytoplasmic PTEN and cell death in cancer cells [<xref ref-type="bibr" rid="B38-cancers-11-01247">38</xref>]. As expected, the loss of cytoplasmic PTEN can lead to excessive PIP3 accumulation and the activation of a host of downstream signaling pathways, the overactivation of which can stimulate cell survival, growth, proliferation, angiogenesis, metabolism, and migration [<xref ref-type="bibr" rid="B39-cancers-11-01247">39</xref>,<xref ref-type="bibr" rid="B40-cancers-11-01247">40</xref>].</p>
</sec>
<sec id="sec3dot2-cancers-11-01247">
<title>3.2. Nuclear PTEN</title>
<p>Accumulating evidence has suggested that compared with cytoplasmic PTEN, nuclear PTEN plays a totally different role in tumor suppression. Multiple clinical studies have detected nuclear PTEN in normal rather than cancer cells [<xref ref-type="bibr" rid="B41-cancers-11-01247">41</xref>,<xref ref-type="bibr" rid="B42-cancers-11-01247">42</xref>]. For example, the loss of nuclear PTEN has been documented in various cancers such as melanoma [<xref ref-type="bibr" rid="B43-cancers-11-01247">43</xref>] and thyroid carcinomas [<xref ref-type="bibr" rid="B41-cancers-11-01247">41</xref>]. An inverse correlation has been reported between nuclear PTEN expression and the mitotic index, suggesting that a lack of nuclear PTEN facilitates tumor cell proliferation [<xref ref-type="bibr" rid="B43-cancers-11-01247">43</xref>]. Moreover, the expression level of nuclear PTEN has been used as a prognostic marker in various cancers [<xref ref-type="bibr" rid="B44-cancers-11-01247">44</xref>,<xref ref-type="bibr" rid="B45-cancers-11-01247">45</xref>]. At the cellular level, nuclear PTEN is critical for chromosome integrity, DNA repair, cell cycle arrest, and genomic stability. Accumulating evidence has suggested that nuclear PTEN functions as a guardian of chromosome integrity. Defective PTEN in mouse embryonic stem cells has been shown to cause genetic instability [<xref ref-type="bibr" rid="B46-cancers-11-01247">46</xref>]. PTEN phosphatase activity is required for maintaining chromosome integrity [<xref ref-type="bibr" rid="B47-cancers-11-01247">47</xref>] and preventing genomic alterations during cell division [<xref ref-type="bibr" rid="B48-cancers-11-01247">48</xref>]. Nuclear PTEN can function as a mitotic phosphatase and physically interact with and dephosphorylate PLK1, thereby preventing polyploidy [<xref ref-type="bibr" rid="B48-cancers-11-01247">48</xref>]. Cells lacking nuclear PTEN are hypersensitive to DNA damage, implying that PTEN plays an important role in DNA repair [<xref ref-type="bibr" rid="B49-cancers-11-01247">49</xref>].</p>
<p>Multiple studies have revealed that nuclear PTEN can function as a brake for uncontrolled cell proliferation and regulate cell cycle progression. During the G1-S transition, nuclear PTEN downregulates cyclin D1 (CDK1) to inhibit G1 progression [<xref ref-type="bibr" rid="B50-cancers-11-01247">50</xref>]. PTEN can also interact with p300 to maintain p53 acetylation, which, in turn, promotes PTEN–p53 interaction and regulates G1 arrest [<xref ref-type="bibr" rid="B51-cancers-11-01247">51</xref>]. Moreover, nuclear PTEN activation has been shown to arrest G2/M progression. An overactivated Notch signaling pathway can lead to PTEN phosphorylation, thus promoting gastric tumorigenesis, whereas dephosphorylated nuclear PTEN can interact with a cyclin B1–CDK1 complex to arrest cells at the prometaphase [<xref ref-type="bibr" rid="B52-cancers-11-01247">52</xref>]. Finally, DNA topoisomerase-2 alpha (TOP2A) mediates DNA decatenation and prevents chromatin entanglement and chromosome bridges during segregation. PTEN has been shown to physically interact with TOP2A to prevent its degradation [<xref ref-type="bibr" rid="B53-cancers-11-01247">53</xref>].</p>
</sec>
<sec id="sec3dot3-cancers-11-01247">
<title>3.3. PTEN in Cell Organelles</title>
<p>Emerging evidence has suggested that PTEN also plays a pivotal role in cell organelles other than the cytoplasm and nucleus. PTEN can function as a protein phosphatase in the endoplasmic reticulum (ER) to regulate ER-induced apoptosis. ER-localized PTEN physically competes with F-box/LRR-repeat protein 2 for type 3 IP3 receptor binding, which inactivates AKT and induces a subsequent ER-to-mitochondrial Ca<sup>2+</sup> transfer, causing Ca<sup>2+</sup>-dependent apoptosis [<xref ref-type="bibr" rid="B54-cancers-11-01247">54</xref>,<xref ref-type="bibr" rid="B55-cancers-11-01247">55</xref>]. PTEN also mediates mitochondria-related apoptosis. One study showed a gradual accumulation of PTEN in the mitochondria of rat hippocampus during staurosporine-induced apoptosis. PTEN was found to increase cellular reactive oxygen species level and activate apoptotic cascades, whereas PTEN knockdown significantly rescued hippocampal cells from apoptotic damage [<xref ref-type="bibr" rid="B56-cancers-11-01247">56</xref>]. Moreover, a recent study has suggested that PTEN plays a critical role in mitochondrial metabolism. This study reported differential mitochondrial oxidative phosphorylation states and bioenergetics in glioblastoma samples with different PTEN mutational statuses [<xref ref-type="bibr" rid="B57-cancers-11-01247">57</xref>].</p>
<p>PTEN localized in the cell nucleolus also exerts tumor-suppressive activity. Nucleolar PTEN is essential for nucleolar homeostasis and morphology. PTEN knockdown has been observed to result in both quantitative and qualitative changes in nucleoli and increased ribosome biogenesis [<xref ref-type="bibr" rid="B58-cancers-11-01247">58</xref>]. As increase in nucleolus and ribosome biogenesis is associated with increased cancer risk [<xref ref-type="bibr" rid="B59-cancers-11-01247">59</xref>], nucleolar PTEN may exert its tumor-suppressive effect via the inhibition of ribosome biogenesis. Furthermore, a recent study has identified a PTEN isoform, PTENβ, which initiates translation from an AUU codon and has an extended 146-amino acid N-terminus. PTENβ has been found to be localized in the nucleolus where it regulates pre-rRNA synthesis by dephosphorylating nucleolin; however, its loss has been found to promote ribosome biogenesis [<xref ref-type="bibr" rid="B60-cancers-11-01247">60</xref>].</p>
<p>PTEN has also been demonstrated to be enriched at the centrosomes and interact with the DLG1/EG5 motor protein complex during cell mitosis, thereby regulating proper mitotic spindle assembly and chromosome segregation [<xref ref-type="bibr" rid="B61-cancers-11-01247">61</xref>]. PTEN may also phosphorylate Dishevelled, DVL, and participate in cilia disassembly and multicilia formation [<xref ref-type="bibr" rid="B62-cancers-11-01247">62</xref>].</p>
<p>PTENα (also termed as PTEN-Long, PTEN-L) is a PTEN isoform whose translation initiates from a CUG codon upstream of the canonical start codon. This isoform has additional 173 (<italic>Homo sapiens</italic>) or 169 (<italic>Mus musculus</italic>) amino acids at the N-terminal region [<xref ref-type="bibr" rid="B63-cancers-11-01247">63</xref>,<xref ref-type="bibr" rid="B64-cancers-11-01247">64</xref>]. Immunofluorescence analysis of GFP-tagged PTENα has revealed that it is colocalized with the mitochondria, where it participates in mitochondrial energy metabolism by regulating cytochrome c oxidase activity. Subsequently, immuno-gold electron microscopy confirmed that PTENα is localized at the outer mitochondrial membrane. Functionally, PTENα impairs PRKN’s E3 ligase activity by preventing its mitochondrial translocation [<xref ref-type="bibr" rid="B64-cancers-11-01247">64</xref>].</p>
</sec>
<sec id="sec3dot4-cancers-11-01247">
<title>3.4. Secreted PTEN</title>
<p>Recent studies have reported that PTEN can be secreted from donor cells and taken up by recipient cells. This finding has revolutionized the concept that PTEN has only intracellular functions. PTEN can be packaged into exosomes and delivered under the control of NEDD4 family-interacting protein 1 (Ndfip1) with Ndfip1/Nedd4-mediated ubiquitination, thereby enhancing PTEN secretion. Exosomal PTEN is available for uptake by recipient cells, resulting in the repression of AKT activation and proliferation [<xref ref-type="bibr" rid="B65-cancers-11-01247">65</xref>]. It has been demonstrated that PTENα can induce a complete tumor regression with a concomitant reduction of pAKT expression in a xenograft mouse model, implying PTENα can enter into neighboring tumor cells leading to tumor suppression [<xref ref-type="bibr" rid="B63-cancers-11-01247">63</xref>]. PTENα is secreted extracellularly and exerts proinflammatory responses [<xref ref-type="bibr" rid="B66-cancers-11-01247">66</xref>], thus suggesting its actions on immune cells. However, the detailed mechanism still needs further investigation. Exosomal PTEN has been considered as a therapeutic target for spinal cord injuries. Retinoic acid receptor β treatment induces the release of PTEN-enriched exosomes from neurons. Astrocytes that take up these exosomes will have reduced proliferation, leading to the inhibition of glial scar formation [<xref ref-type="bibr" rid="B67-cancers-11-01247">67</xref>]. Moreover, PTENα can be secreted in the native form and be taken up by recipient cells. Secreted PTENα has been shown to be able to inhibit the PI3K pathway in a mouse model [<xref ref-type="bibr" rid="B63-cancers-11-01247">63</xref>]. Several clinical studies have reported mutant forms of PTEN that could be detected in the biofluids of glioblastoma patients [<xref ref-type="bibr" rid="B68-cancers-11-01247">68</xref>,<xref ref-type="bibr" rid="B69-cancers-11-01247">69</xref>]. Reportedly, mutant PTEN proteins may act in a dominant-negative manner to suppress the function of wild-type PTEN through dimerization [<xref ref-type="bibr" rid="B70-cancers-11-01247">70</xref>]. Thus, it will be of interest to determine whether cancer cells can secrete mutant PTEN to suppress wild-type PTEN function in recipient cells.</p>
</sec>
</sec>
<sec id="sec4-cancers-11-01247">
<title>4. PTEN and Cancer Hallmarks</title>
<p>The link between <italic>PTEN</italic> and cancer was first established in 1997 when <italic>PTEN</italic> mutations were identified in multiple advanced tumors [<xref ref-type="bibr" rid="B3-cancers-11-01247">3</xref>]. Overwhelming evidence has shown that <italic>PTEN</italic> loss of function occurs in a broad spectrum of human cancers. The highest percentage of <italic>PTEN</italic> aberrations has been found in uterine cancer, glioblastoma multiforme, and prostate cancer based on the data from the cBioPortal database (<xref ref-type="fig" rid="cancers-11-01247-f005">Figure 5</xref>A). This revealed the highest alteration frequency of <italic>PTEN</italic> in uterine cancer. Missense mutations account for the predominant genetic alteration in uterine cancer. However, deep deletions of <italic>PTEN</italic> are far more frequent in prostate cancer patients. Our speculation is that since <italic>PTEN</italic> loss in prostate cancer is associated with more advanced metastatic disease, the complete deletion of the <italic>PTEN</italic> gene may therefore be more prevalent [<xref ref-type="bibr" rid="B71-cancers-11-01247">71</xref>]. On the contrary, in uterine cancer patients, <italic>PTEN</italic> is frequently mutated in Type I endometrioid carcinoma, which is associated with good prognosis [<xref ref-type="bibr" rid="B72-cancers-11-01247">72</xref>]. Missense mutations, in this case, may have less deleterious effects on PTEN, and with its tumor suppressor functions being partially preserved.</p>
<p><italic>PTEN</italic> loss of function is one of the most frequent events in cancers. The cBioPortal sequence data have underestimated the actual frequency of <italic>PTEN</italic> alterations. A meta-analysis has reported that the loss of PTEN protein was found in 78% glioblastoma patients and 48% endometrial tumor patients. Another study has revealed that deletions, including the <italic>PTEN</italic> locus in The Cancer Genome Atlas (TCGA database), have been identified in 143/170 (85%) of glioblastomas [<xref ref-type="bibr" rid="B73-cancers-11-01247">73</xref>]. Even without the evidence of <italic>PTEN</italic> genetic changes, a considerable proportion of glioblastoma patients have reportedly shown reduced <italic>PTEN</italic> mRNA expression. Moreover, methylation of the <italic>PTEN</italic> promoter has been demonstrated to be a hallmark of cancers such as low-grade glioma and melanoma [<xref ref-type="bibr" rid="B74-cancers-11-01247">74</xref>,<xref ref-type="bibr" rid="B75-cancers-11-01247">75</xref>].</p>
<p><italic>PTEN</italic> follows the “continuum model of tumor suppression” instead of the classical two-hit hypothesis, involving subtle expression changes that may influence tumor progression even without the loss of an allele [<xref ref-type="bibr" rid="B76-cancers-11-01247">76</xref>]. Accumulating evidence has suggested that partial loss of PTEN function is sufficient for promoting tumor initiation and progression [<xref ref-type="bibr" rid="B77-cancers-11-01247">77</xref>]. In addition, one study that used a hypomorphic <italic>Pten</italic> mouse model with reduced PTEN levels also demonstrated that subtle reduction in PTEN expression is enough to confer cancer susceptibility [<xref ref-type="bibr" rid="B78-cancers-11-01247">78</xref>]. Dysregulation of PTEN expression can be attributed to multiple mechanisms, including transcription, miRNA or ncRNA targeting, and protein stability. For example, transcriptional silencing of <italic>PTEN</italic> by promoter hypermethylation has been reported in endometrial cancer, glioblastoma, and lung cancer [<xref ref-type="bibr" rid="B79-cancers-11-01247">79</xref>,<xref ref-type="bibr" rid="B80-cancers-11-01247">80</xref>,<xref ref-type="bibr" rid="B81-cancers-11-01247">81</xref>]. Moreover, post-transcriptional changes in <italic>PTEN</italic> have also been revealed to be crucial in tumorigenesis [<xref ref-type="bibr" rid="B82-cancers-11-01247">82</xref>].</p>
<p>It has been found that <italic>PTEN</italic> is concurrently mutated with specific genetic alterations such as <italic>TMPRSS2-ERG</italic> gene fusion and <italic>TP53</italic> mutation. <italic>TMPRSS2-ERG</italic> gene fusion and <italic>PTEN</italic> mutation have been revealed to drive prostate carcinogenesis cooperatively [<xref ref-type="bibr" rid="B83-cancers-11-01247">83</xref>]. Indeed, the concurrence of <italic>TMPRSS2-ERG</italic> gene fusion and <italic>PTEN</italic> loss is associated with poor outcome [<xref ref-type="bibr" rid="B84-cancers-11-01247">84</xref>]. The reason for this coexistence is unknown, but it has been pointed out that <italic>TMPRSS2-ERG</italic> fusion may facilitate the generation of <italic>PTEN</italic> deletions [<xref ref-type="bibr" rid="B85-cancers-11-01247">85</xref>]. It has been reported that <italic>TMPRSS2-ERG</italic> alone is insufficient to drive tumorigenesis. Such collaboration may confer a selective advantage to promote precancerous lesions to aggressive cancer [<xref ref-type="bibr" rid="B86-cancers-11-01247">86</xref>].</p>
<p><italic>TP53</italic> is another gene mutated concurrently with <italic>PTEN</italic> in cancers of the prostate, cervix, and breast (<xref ref-type="fig" rid="cancers-11-01247-f005">Figure 5</xref>B). A combination of <italic>Pten</italic> and <italic>Trp53</italic> loss has been found to drive a prostate tumor progression in a mouse model [<xref ref-type="bibr" rid="B87-cancers-11-01247">87</xref>]. Activation of PI3K pathway promotes MDM2-dependent p53 degradation, while ectopic PTEN overexpression can stabilize p53 by increasing its half-life [<xref ref-type="bibr" rid="B88-cancers-11-01247">88</xref>]. In addition, PTEN can regulate <italic>TP53</italic> transcriptional activity [<xref ref-type="bibr" rid="B89-cancers-11-01247">89</xref>], in turn, <italic>PTEN</italic> is a transcriptional target of p53 [<xref ref-type="bibr" rid="B90-cancers-11-01247">90</xref>,<xref ref-type="bibr" rid="B91-cancers-11-01247">91</xref>]. Overall, PTEN-p53 may form a self-reinforced circuit, the dysfunction of which may promote tumorigenesis.</p>
<sec id="sec4dot1-cancers-11-01247">
<title>4.1. PTEN and Oncogenic Signaling</title>
<p>The role of PTEN loss in tumorigenesis is highly complex, and hyperactivation of the PI3K pathway is clearly the major oncogenic signaling output. Indeed, PIK3CA, which encodes the α subunit of PI3K, is also frequently altered in various cancers [<xref ref-type="bibr" rid="B92-cancers-11-01247">92</xref>,<xref ref-type="bibr" rid="B93-cancers-11-01247">93</xref>,<xref ref-type="bibr" rid="B94-cancers-11-01247">94</xref>]. The classical tumor suppressor function of PTEN is mainly dependent on its lipid phosphatase activity, which dephosphorylates PIP3 and thereby inhibits the phosphoinositide 3-kinase PI3K signaling pathway [<xref ref-type="bibr" rid="B15-cancers-11-01247">15</xref>]. The activation state of the PI3K pathway is normally measured based on the levels of AKT phosphorylation, and aberrant AKT upregulation is frequently observed in both early and advanced cancers [<xref ref-type="bibr" rid="B95-cancers-11-01247">95</xref>]. Activated AKT regulates downstream genes such as those of epidermal growth factor receptor, vascular endothelial growth factor (VEGF) receptors, mitogen-activated protein kinase (MAPK), caspase-9, and mammalian target of rapamycin (mTOR) [<xref ref-type="bibr" rid="B96-cancers-11-01247">96</xref>,<xref ref-type="bibr" rid="B97-cancers-11-01247">97</xref>]. Pathways related to all of these genes have been found to be essential for multiple biological processes, including cell survival, cell migration/invasion, and cell cycle progression. However, the consequences of AKT1, AKT2, and AKT3 ablation have been reported to be quite different. AKT1 knockdown has an anti-tumor effect, whereas AKT2 ablation can promote tumor growth and AKT3 ablation has little effect [<xref ref-type="bibr" rid="B98-cancers-11-01247">98</xref>].</p>
</sec>
<sec id="sec4dot2-cancers-11-01247">
<title>4.2. PTEN and Cell Cycle</title>
<p>The role of PTEN in cell cycle regulation has been widely studied. PTEN loss has been found to exert pro-tumorigenic effects through cell cycle dysregulation. In one study, <italic>Pten</italic> deletion in mouse astrocytes led to accelerated proliferation both in vitro and in vivo [<xref ref-type="bibr" rid="B99-cancers-11-01247">99</xref>]. PTEN reintroduction to PTEN-null glioblastoma cell lines was found to suppress cell proliferation by inducing G1 arrest through p27Kip1 upregulation, which inhibited downstream cyclin-dependent kinase 2 activity [<xref ref-type="bibr" rid="B100-cancers-11-01247">100</xref>]. In leukemia, PTEN expression reduced the proliferation of leukemic T cells through all phases of the cell cycle [<xref ref-type="bibr" rid="B101-cancers-11-01247">101</xref>]. Furthermore, simultaneous inactivation of one <italic>Pten</italic> allele and one or more Cdkn1b (encoding p27Kip1) alleles accelerated neoplastic transformation and increased tumor incidence in a mouse prostate cancer model [<xref ref-type="bibr" rid="B102-cancers-11-01247">102</xref>], implying that p27Kip1 plays a crucial role in mediating the tumor-suppressive effect of PTEN.</p>
</sec>
<sec id="sec4dot3-cancers-11-01247">
<title>4.3. PTEN and Cancer Genome Stability</title>
<p>Nuclear PTEN is a guardian of genome integrity. Reportedly, PTEN loss is associated with aneuploidy in human primary breast cancer cells [<xref ref-type="bibr" rid="B46-cancers-11-01247">46</xref>]. Nuclear PTEN localizes to the centromeres to maintain chromosome stability by physically interacting with CENP-C, an integral part of the kinetochore that is essential for proper chromosome segregation during mitosis [<xref ref-type="bibr" rid="B47-cancers-11-01247">47</xref>,<xref ref-type="bibr" rid="B103-cancers-11-01247">103</xref>]. Disruption of PTEN and centromeres can lead to chromosomal instability, which is a hallmark of cancer [<xref ref-type="bibr" rid="B47-cancers-11-01247">47</xref>]. More recently, PTEN has been shown to regulate spindle pole architecture and movement by directly interacting with DLG1/EG5 through its PDZ-BM. PDZ-BM-lacking cells are prone to chromosome missegregation, and PDZ-BM-lacking mice are susceptible to lymphomas and breast cancer development [<xref ref-type="bibr" rid="B61-cancers-11-01247">61</xref>,<xref ref-type="bibr" rid="B104-cancers-11-01247">104</xref>].</p>
</sec>
<sec id="sec4dot4-cancers-11-01247">
<title>4.4. PTEN and Cellular Energetics</title>
<p>Overwhelming evidence revealed that cancer cells undergo reprogramming of their metabolic pathways to sustain rapid proliferation and growth. Most cancer cells derive their energy from glycolysis instead of oxidative phosphorylation, an adaptive mechanism referred to as the Warburg effect [<xref ref-type="bibr" rid="B105-cancers-11-01247">105</xref>]. A <italic>Pten</italic> transgenic mouse model has demonstrated PTEN to be a negative regulator of glycolysis [<xref ref-type="bibr" rid="B106-cancers-11-01247">106</xref>]. Indeed, PTEN loss can lead to a plethora of metabolic changes, mostly through the activation of downstream PI3K-AKT pathway [<xref ref-type="bibr" rid="B107-cancers-11-01247">107</xref>]. Haploinsufficiency of <italic>Pten</italic> has been demonstrated to hypersensitize insulin-stimulated glucose uptake both in vitro and in vivo [<xref ref-type="bibr" rid="B108-cancers-11-01247">108</xref>]. The PI3K/PKB pathway is essential to maintain the normal glucose homeostasis, while the PTEN deficiency-induced PI3K-AKT activation is responsible for the translocation of Glucose transporter type 4 (GLUT4) [<xref ref-type="bibr" rid="B109-cancers-11-01247">109</xref>,<xref ref-type="bibr" rid="B110-cancers-11-01247">110</xref>]. PTEN loss induced PI3K-AKT activation also inhibits forkhead box protein O1 (FOXO1) and proliferator-activated receptor-γ (PPARγ), thus affecting hepatic gluconeogenesis [<xref ref-type="bibr" rid="B111-cancers-11-01247">111</xref>,<xref ref-type="bibr" rid="B112-cancers-11-01247">112</xref>]. Moreover, AKT activation promotes ATP hydrolysis, resulting in a compensatory increase in aerobic glycolysis through the upregulation of ENTPD5 [<xref ref-type="bibr" rid="B113-cancers-11-01247">113</xref>]. PTEN loss also affects lipid and protein synthesis. Inactivation of PTEN promotes aberrant sterol regulatory element-binding proteins (SREBP)-dependent lipogenesis, thus driving metastatic progression in a mouse prostate tumor model [<xref ref-type="bibr" rid="B114-cancers-11-01247">114</xref>]. mTORC1 activation due to PTEN loss upregulates 4E-binding protein 1 (4EBP1) and p70S6 kinase, which enhances pro-tumorigenic protein synthesis, contributing to tumor growth [<xref ref-type="bibr" rid="B115-cancers-11-01247">115</xref>]. It has been reported that mTORC1 mediates S-adenosylmethionine decarboxylase 1 (AMD1) stability and affects polyamine synthesis, which is essential for the transformation of oncogenic metabolic program [<xref ref-type="bibr" rid="B116-cancers-11-01247">116</xref>]. In addition, PTEN elevation in a super <italic>Pten</italic> mouse model can negatively regulate glutaminolysis and the Warburg effect, resulting in an anti-tumor metabolism in vivo [<xref ref-type="bibr" rid="B117-cancers-11-01247">117</xref>].</p>
</sec>
<sec id="sec4dot5-cancers-11-01247">
<title>4.5. PTEN and Metastasis</title>
<p>PTEN loss plays a vital role in tumor metastasis and invasion. Some clinical studies have revealed a high risk of tumor metastasis in patients with PTEN inactivation [<xref ref-type="bibr" rid="B118-cancers-11-01247">118</xref>,<xref ref-type="bibr" rid="B119-cancers-11-01247">119</xref>]. In addition, PTEN mutation has been identified as one of the most prevalent events in metastatic cancers [<xref ref-type="bibr" rid="B120-cancers-11-01247">120</xref>]. The mechanism involved is highly complex, and PTEN alteration alone is insufficient to confer all metastatic traits [<xref ref-type="bibr" rid="B87-cancers-11-01247">87</xref>,<xref ref-type="bibr" rid="B121-cancers-11-01247">121</xref>]. In a mouse prostate cancer model, PTEN loss has been shown to function as a second hit for the activation of the oncogenic RAS/MAPK pathway [<xref ref-type="bibr" rid="B122-cancers-11-01247">122</xref>]. Cooperation between PTEN inactivation and RAS activation has also been reported to drive melanoma metastasis [<xref ref-type="bibr" rid="B123-cancers-11-01247">123</xref>]. In a <italic>Pten</italic>-null murine prostate cancer model, activated AKT could directly phosphorylate WHSC1 to prevent its degradation, and increased WHSC1 further enhanced AKT activity in a feedforward manner to promote prostate cancer metastasis [<xref ref-type="bibr" rid="B124-cancers-11-01247">124</xref>]. In addition, several pathways involving NOTCH [<xref ref-type="bibr" rid="B125-cancers-11-01247">125</xref>], BRAF [<xref ref-type="bibr" rid="B126-cancers-11-01247">126</xref>], and SMAD4 [<xref ref-type="bibr" rid="B127-cancers-11-01247">127</xref>] have been reported to cooperate with PTEN to trigger tumor metastasis. PTEN loss may also confer invasive capability. Some in vitro studies have revealed that PTEN impairs cell migration in both phosphatase-dependent and -independent manners [<xref ref-type="bibr" rid="B128-cancers-11-01247">128</xref>,<xref ref-type="bibr" rid="B129-cancers-11-01247">129</xref>,<xref ref-type="bibr" rid="B130-cancers-11-01247">130</xref>]. Moreover, PTEN inhibition has been demonstrated to enhance tumor invasiveness in vivo [<xref ref-type="bibr" rid="B131-cancers-11-01247">131</xref>].</p>
</sec>
<sec id="sec4dot6-cancers-11-01247">
<title>4.6. PTEN and Angiogenesis</title>
<p>Angiogenesis is a biological process involving the generation of new blood vessels from preexisting vasculature, which is vital for normal tissue development and wound healing. Pathological angiogenesis is an important hallmark of cancer, which is a fundamental step in the transition from the benign state to the malignant state [<xref ref-type="bibr" rid="B132-cancers-11-01247">132</xref>]. A previous study has reported that PTEN reconstitution can significantly suppress angiogenic activity via PI3K-dependent regulation in a nude mouse orthotopic brain tumor model [<xref ref-type="bibr" rid="B133-cancers-11-01247">133</xref>], suggesting that PTEN also plays a role in controlling tumor-induced angiogenesis. In a zebrafish model, haploinsufficient PTEN has shown to result in enhanced VEGF expression and vessel hyperplasia [<xref ref-type="bibr" rid="B134-cancers-11-01247">134</xref>]. Reintroduction of PTEN C2 domain also inhibited HepG2 induced-angiogenesis and VEGF expression both in vitro and in vivo, suggesting that PTEN can inhibit VEGF-mediated angiogenesis in a PI3K-independent manner [<xref ref-type="bibr" rid="B135-cancers-11-01247">135</xref>]. PTEN loss in endothelial cell activates the Notch pathway, excessive activation of which can result in vascular hyperplasia [<xref ref-type="bibr" rid="B136-cancers-11-01247">136</xref>].</p>
</sec>
</sec>
<sec id="sec5-cancers-11-01247">
<title>5. Regulation of PTEN in Physiological and Pathological States</title>
<p>The multifaceted nature of PTEN tumor suppressor is regulated by the complex modulation of its transcription, translation, catalytic activity, subcellular distribution, and interactions with other signaling molecules. Because these topics have been reviewed in the past, we will only focus on more recent significant findings related to the mechanisms of PTEN regulation.</p>
<sec id="sec5dot1-cancers-11-01247">
<title>5.1. miRNAs and LncRNAs</title>
<p>MicroRNAs (miRNAs) and long-noncoding RNAs (LncRNAs) contribute to the regulation of PTEN protein level in many cancers at the post-transcriptional level. There are several miRNAs found to bind the 3′-UTR of <italic>PTEN</italic>, among them the most prominent one is miR-21. miR-21 is one of the most frequently overexpressed microRNAs in human cancer, which directly targets <italic>PTEN</italic> mRNA and negatively regulates PTEN protein level, thus promoting cell growth and metastasis [<xref ref-type="bibr" rid="B137-cancers-11-01247">137</xref>]. Other oncomiR such as miR-23a [<xref ref-type="bibr" rid="B131-cancers-11-01247">131</xref>], miR-26a [<xref ref-type="bibr" rid="B138-cancers-11-01247">138</xref>], miR-92a [<xref ref-type="bibr" rid="B139-cancers-11-01247">139</xref>], miR-130a [<xref ref-type="bibr" rid="B140-cancers-11-01247">140</xref>], miR-205-5p [<xref ref-type="bibr" rid="B141-cancers-11-01247">141</xref>], and miR-425 [<xref ref-type="bibr" rid="B142-cancers-11-01247">142</xref>] are also reported to negatively regulate <italic>PTEN</italic> expression and activated PI3K-AKT signaling pathway, which positively contributed to tumor initiation, progression, and metastasis. Furthermore, the pseudogene of <italic>PTEN</italic>, <italic>PTEN</italic> pseudogene 1 (<italic>PTENP1</italic>), shares extensive sequence similarity with <italic>PTEN</italic> mRNA in regions that harbor miRNA target sites. Thus, it functions like a miRNA sponge, restoring the <italic>PTEN</italic> mRNA level and enhancing its tumor suppressor activity [<xref ref-type="bibr" rid="B143-cancers-11-01247">143</xref>]. Overexpression or exosome transmitted <italic>PTENP1</italic> suppressed cancer cell proliferation and tumor progression [<xref ref-type="bibr" rid="B144-cancers-11-01247">144</xref>,<xref ref-type="bibr" rid="B145-cancers-11-01247">145</xref>,<xref ref-type="bibr" rid="B146-cancers-11-01247">146</xref>].</p>
</sec>
<sec id="sec5dot2-cancers-11-01247">
<title>5.2. Catalytic Activity</title>
<sec id="sec5dot2dot1-cancers-11-01247">
<title>5.2.1. PIP2</title>
<p>PTEN catalytic activity is regulated through an allosteric mechanism involving the binding of anionic phospholipids to the N-terminal PBM of PTEN [<xref ref-type="bibr" rid="B10-cancers-11-01247">10</xref>,<xref ref-type="bibr" rid="B147-cancers-11-01247">147</xref>]. This regulation is highly specific as the addition of only PI(4,5)P2 and PI(5)P can stimulate the catalytic activity of PTEN. Furthermore, only di-C8 fatty acid but not di-C4 fatty acid is active. Spectroscopic evidence suggests that PIP2 binding induces a conformational change associated with an increased α-helicity [<xref ref-type="bibr" rid="B148-cancers-11-01247">148</xref>]. The residues within the PTEN PBM that mediate this allosteric stimulation are K13, R14, and R15 [<xref ref-type="bibr" rid="B10-cancers-11-01247">10</xref>]. Notably, PTEN N-terminal PBM has been implicated in nuclear localization through the ubiquitination of K13 residue [<xref ref-type="bibr" rid="B22-cancers-11-01247">22</xref>]. Whether ubiquitination at K13 affects PIP2 binding and/or enzymatic activation is not yet clear. It is possible that PIP2 binding and PBM ubiquitination are mutually exclusive. It is speculated that their relative contributions determine the extent of PTEN subcellular distribution on the cell membrane and nucleus.</p>
</sec>
<sec id="sec5dot2dot2-cancers-11-01247">
<title>5.2.2. Phosphorylation</title>
<p>Phosphorylation of PTEN C-terminal tail region between residues 360 and 385 inhibits the phosphatase activity of PTEN. More than 10 intracellular kinases are known to mediate the direct phosphorylation of PTEN. For example, BCR-ABL interacts with CKII, and this complex suppresses the catalytic activity of PTEN through phosphorylation of its C-terminal tail region [<xref ref-type="bibr" rid="B149-cancers-11-01247">149</xref>]. NMR has revealed that phosphorylation events in two clusters—namely S380–S385 (cluster I) and S361–S370 (cluster II)—are mediated by CKII and GSK-3β, respectively [<xref ref-type="bibr" rid="B150-cancers-11-01247">150</xref>]. Phosphorylation in cluster I is an ordered event occurring in the following sequence: S385 &gt; S380 &gt; T383 &gt; T382. For cluster II, the order is S370 &gt; T366 &gt; S362 &gt; S361 &gt; T363. Phosphorylated PTEN tail is believed to mask the N-terminal catalytic domain or C-terminal C2 domain through intramolecular interactions [<xref ref-type="bibr" rid="B16-cancers-11-01247">16</xref>,<xref ref-type="bibr" rid="B151-cancers-11-01247">151</xref>,<xref ref-type="bibr" rid="B152-cancers-11-01247">152</xref>,<xref ref-type="bibr" rid="B153-cancers-11-01247">153</xref>]. Screening for PTEN mutants displaying greater membrane-binding capacity has revealed that Q17, R41, E73, N262, and N329 residues mediate the intramolecular interactions with the C-tail [<xref ref-type="bibr" rid="B154-cancers-11-01247">154</xref>,<xref ref-type="bibr" rid="B155-cancers-11-01247">155</xref>]. Indeed, these residues are distributed in the catalytic pocket and membrane-facing surfaces of PTEN. Mutation of these residues significantly enhanced the intrinsic phosphatase activity of PTEN [<xref ref-type="bibr" rid="B154-cancers-11-01247">154</xref>,<xref ref-type="bibr" rid="B155-cancers-11-01247">155</xref>]. Overall, phosphorylation in the C-terminal tail region induced a closed, inactive conformation that prevented membrane binding, whereas reduction of the extent of phosphorylation resulted in an open, active confirmation. We profiled the mutational status of the 10 known phosphorylation sites between residues 336 and 401 in human cancers but detected only some sparing mutations (<xref ref-type="fig" rid="cancers-11-01247-f003">Figure 3</xref>). This was expected because mutations in these residues are predicted to enhance PTEN membrane binding and catalytic activities. Notably, we identified the putative phosphorylation sites at Y27, Y46, Y68, Y155, and Y174, which displayed greater mutational frequency. Their roles in PTEN function are not yet clear.</p>
</sec>
<sec id="sec5dot2dot3-cancers-11-01247">
<title>5.2.3. Redox</title>
<p>Hydrogen peroxide-mediated oxidation inactivates PTEN catalytic activity by the formation of disulfide bridge between C124 and C71 in the catalytic pocket [<xref ref-type="bibr" rid="B156-cancers-11-01247">156</xref>,<xref ref-type="bibr" rid="B157-cancers-11-01247">157</xref>]. The reactivation of oxidized PTEN has been shown to be mediated by thioredoxin [<xref ref-type="bibr" rid="B156-cancers-11-01247">156</xref>,<xref ref-type="bibr" rid="B158-cancers-11-01247">158</xref>,<xref ref-type="bibr" rid="B159-cancers-11-01247">159</xref>] and glutathione [<xref ref-type="bibr" rid="B160-cancers-11-01247">160</xref>]. However, some derivatives of organic peroxides, such as the tumor-promoting <italic>tert</italic>-butyl hydroperoxide, have been shown to irreversibly oxidize and inactivate PTEN [<xref ref-type="bibr" rid="B161-cancers-11-01247">161</xref>]. This irreversible redox regulation of PTEN may be a mechanism underlying the tumor-promoting actions of these agents. As per the COSMIC database, C124 and C71 have 29 and 13 missense mutations, respectively, in endometrial, breast, brain, prostate, and larger intestine cancers.</p>
</sec>
<sec id="sec5dot2dot4-cancers-11-01247">
<title>5.2.4. Ubiquitination</title>
<p>A rather unusual observation is that the Ret finger protein (RFP), a E3 ligase of PTEN, mediates atypical ubiquitination of PTEN on multiple lysine residues in the C2 domain. Interestingly, these modifications do not alter PTEN protein turnover or localization but instead reduce its lipid phosphatase activity by more than 10-fold [<xref ref-type="bibr" rid="B162-cancers-11-01247">162</xref>].</p>
</sec>
</sec>
<sec id="sec5dot3-cancers-11-01247">
<title>5.3. Membrane Targeting</title>
<p>The ability of PTEN to interact with the lipid bilayer is crucial for its tumor-suppressive activity. Using total reflection internal microscopy imaging techniques, it was estimated that PTEN interacts with the cell membrane for less than 200 ms [<xref ref-type="bibr" rid="B35-cancers-11-01247">35</xref>]. This finding is consistent with the results of most immunofluorescence analysis studies showing that PTEN is preferentially localized to the cytoplasm instead of the cell membrane. However, this notion is disputed by the findings of super-resolution light microscopy, which showed that PTEN is in fact localized to endosomal vesicles tethered to microtubules through PI(3)P [<xref ref-type="bibr" rid="B163-cancers-11-01247">163</xref>]. Again, the CBRIII motif in the C2 domain of PTEN mediates this interaction. Notably, PTEN displays sequence homology to auxilin, a protein essential for endocytosis, and is recruited to clathrin-coated vesicles [<xref ref-type="bibr" rid="B164-cancers-11-01247">164</xref>].</p>
<p>The C-terminal tail region of PTEN plays an important regulatory role in controlling PTEN binding to the lipid bilayer. In general, the phosphorylated tail blocks PTEN from the membrane by physically interacting with the C2 domain via intramolecular interactions [<xref ref-type="bibr" rid="B153-cancers-11-01247">153</xref>,<xref ref-type="bibr" rid="B165-cancers-11-01247">165</xref>]. This assertion is supported by molecular dynamic simulation and has been validated by neutron reflectometry, which revealed the unstructured tail region tugging closely to the C2 domain, thereby blocking the membrane access region. In contrast, the tail region is repelled from the negative anionic phospholipid bilayer, thus allowing the C2 domain to bind to the membrane surface [<xref ref-type="bibr" rid="B165-cancers-11-01247">165</xref>]. Random mutagenesis analysis in <italic>Dictyostelium discoideum</italic> revealed that mutant residues in the catalytic pocket (C124R), CBR3 (N262Y, K69E), Cα2 (N329H, N329I), and C-tail (Y379C/H/N, S380P/Y, D381V, T382I, T383I) enhanced the membrane-binding capacity, suggesting their involvement in an auto-inhibitory function [<xref ref-type="bibr" rid="B154-cancers-11-01247">154</xref>]. Protein semi-synthesis and photo-crosslinking methods have demonstrated that each of the individual phosphorylation sites at S380, T382, T383, and S385 in the C-tail region contributed incrementally to the auto-inhibitory activity [<xref ref-type="bibr" rid="B166-cancers-11-01247">166</xref>]. In the <italic>D. discoideum</italic> system, single-molecule imaging analysis revealed a ‘hopping’ mode of interaction between PTEN and the plasma membrane. This is mediated by the Cα2 helix of the C2 domain of PTEN [<xref ref-type="bibr" rid="B167-cancers-11-01247">167</xref>]. As indicated above, PTEN-L is a long isoform of PTEN and is secreted into the extracellular space. Interestingly, hydrogen/deuterium exchange mass spectroscopy showed that PTEN-L has a membrane-binding element helix between residues 151 and 174 that alters the membrane-binding mechanism from the “hopping” to “scooting” mode [<xref ref-type="bibr" rid="B168-cancers-11-01247">168</xref>]. These PTEN isoforms together with the complex combination of phosphorylation events generate diversity in the catalytic and membrane-binding capacities of PTEN proteins. Based on the COSMIC database, none of the above-mentioned residues except C124 are subjected to significant mutational alterations (<xref ref-type="fig" rid="cancers-11-01247-f003">Figure 3</xref>). This is expected because mutation would likely lead to greater membrane recruitment.</p>
</sec>
<sec id="sec5dot4-cancers-11-01247">
<title>5.4. Stability</title>
<p>PTEN is a stable protein with reported half-live of &gt;12 h [<xref ref-type="bibr" rid="B35-cancers-11-01247">35</xref>,<xref ref-type="bibr" rid="B169-cancers-11-01247">169</xref>]. The stability of PTEN is controlled by two key biochemical events: phosphorylation and ubiquitination. Numerous studies have demonstrated that the phosphorylation of PTEN C-tail confers stability presumably by rendering it in a closed conformation that can protect proteolysis-sensitive sites from protein degradation. Indeed, the substitutions of four frequently phosphorylated sites at residues S380, T382, T383, and S385 with alanine or the PTEN-4A mutant drastically reduced PTEN half-live by six fold [<xref ref-type="bibr" rid="B30-cancers-11-01247">30</xref>]. Similarly, deleting the entire C-tail also reduced the stability of PTEN [<xref ref-type="bibr" rid="B35-cancers-11-01247">35</xref>]. Indeed, mice carrying a <italic>Pten</italic> gene lacking the C-terminal tail region, <italic>Pten<sup>Δ</sup></italic><sup>C</sup>, harbored multiple tumors [<xref ref-type="bibr" rid="B170-cancers-11-01247">170</xref>]. For ubiquitination, polyubiquitination at K13 and K289 has been intimately linked to its proteasome-mediated degradation [<xref ref-type="bibr" rid="B171-cancers-11-01247">171</xref>]. Numerous E3 ligases and deubiquitinases have been identified and are being reviewed extensively by other groups [<xref ref-type="bibr" rid="B12-cancers-11-01247">12</xref>,<xref ref-type="bibr" rid="B153-cancers-11-01247">153</xref>,<xref ref-type="bibr" rid="B172-cancers-11-01247">172</xref>]. A few E3 ligases for PTEN are of relevance to cancer. NEDD4 is the first known E3 ligase that mediates PTEN degradation [<xref ref-type="bibr" rid="B171-cancers-11-01247">171</xref>,<xref ref-type="bibr" rid="B173-cancers-11-01247">173</xref>]. NEDD4 overexpression has been observed in multiple human tumors [<xref ref-type="bibr" rid="B174-cancers-11-01247">174</xref>]. Furthermore, antagonistic actions between NEDD4-1 and CK1α regulate PTEN stability in lung tumor growth [<xref ref-type="bibr" rid="B175-cancers-11-01247">175</xref>]. CHIP, the chaperone-associated E3 ligase, binds to and mediates direct ubiquitination and degradation of PTEN. Indeed, the levels of PTEN and CHIP display an inverse relation in human prostate cancer [<xref ref-type="bibr" rid="B176-cancers-11-01247">176</xref>]. Another NEDD4 family member, WWP2, also referred to as atropine-1-interacting protein 2, is another E3 ligase for PTEN [<xref ref-type="bibr" rid="B177-cancers-11-01247">177</xref>]. The ability of WWP2 to degrade PTEN has been implicated in melanoma [<xref ref-type="bibr" rid="B178-cancers-11-01247">178</xref>] and endometrial cancer development [<xref ref-type="bibr" rid="B179-cancers-11-01247">179</xref>]. WWP2 is downregulated by Cdh1, another E3 ligase that drives M to G1 cell cycle progression [<xref ref-type="bibr" rid="B180-cancers-11-01247">180</xref>]. In fact, WWP2-knockout mice have shown reduced body size and increased PTEN protein levels [<xref ref-type="bibr" rid="B181-cancers-11-01247">181</xref>]. Finally, OTUD3, an ovarian tumor protease family member of E3 deubiquitinase, has been shown to increase PTEN stability [<xref ref-type="bibr" rid="B182-cancers-11-01247">182</xref>]. Indeed, OTUD3 transgenic mice have shown reduced tumorigenic potential and high protein levels. In fact, human cancers harbor missense mutations in OTUD3 that abolish its ability to enhance PTEN protein levels. More recently, PTEN has been shown to drive a feedforward mechanism of upregulating the transcription of its own deubiquitinase USP11. USP11-deficient mice are susceptible to PTEN-dependent tumors [<xref ref-type="bibr" rid="B183-cancers-11-01247">183</xref>]. Indeed, E3 ligase-targeting drugs are being developed to increase PTEN levels in human cancers [<xref ref-type="bibr" rid="B184-cancers-11-01247">184</xref>,<xref ref-type="bibr" rid="B185-cancers-11-01247">185</xref>,<xref ref-type="bibr" rid="B186-cancers-11-01247">186</xref>]. Notably, numerous mutations in the PTEN gene associated with PTEN hamartoma tumor syndrome are known to affect protein stability without affecting the polyubiquitination sites [<xref ref-type="bibr" rid="B187-cancers-11-01247">187</xref>].</p>
</sec>
<sec id="sec5dot5-cancers-11-01247">
<title>5.5. Nuclear Targeting</title>
<p>Sequences responsible for the nuclear-cytoplasmic partitioning of PTEN are mainly confined to the N-terminal region (see <xref ref-type="sec" rid="sec2dot1-cancers-11-01247">Section 2.1</xref>. above) [<xref ref-type="bibr" rid="B188-cancers-11-01247">188</xref>]. PPTMs by ubiquitination and sumoylation play critical roles in controlling the translocation, exclusion, and retention of PTEN in the nucleus. Monoubiquitination at K13 and K289 and sumoylation at K254 promote PTEN nuclear translocation and retention, respectively [<xref ref-type="bibr" rid="B22-cancers-11-01247">22</xref>,<xref ref-type="bibr" rid="B49-cancers-11-01247">49</xref>]. The E3 ligases responsible for PTEN ubiquitination are NEDD4-1 and XIAP [<xref ref-type="bibr" rid="B22-cancers-11-01247">22</xref>,<xref ref-type="bibr" rid="B189-cancers-11-01247">189</xref>], and PIASxα has been implicated as the E3 ligase responsible for PTEN sumoylation [<xref ref-type="bibr" rid="B190-cancers-11-01247">190</xref>]. PTEN in the cell nucleus is deubiquitinated by the HAUSP enzyme and then excluded [<xref ref-type="bibr" rid="B191-cancers-11-01247">191</xref>]. PTEN has also been shown to enter the nucleus through passive diffusion, which is mediated by the major vault protein [<xref ref-type="bibr" rid="B38-cancers-11-01247">38</xref>,<xref ref-type="bibr" rid="B192-cancers-11-01247">192</xref>,<xref ref-type="bibr" rid="B193-cancers-11-01247">193</xref>]. Based on the COSMIC database, very few mutations have been noted at K254, K266, and K289 (<xref ref-type="fig" rid="cancers-11-01247-f003">Figure 3</xref>).</p>
<p>The nuclear-cytoplasmic partitioning of PTEN is modulated by a host of positive and negative regulators. The following factors promote PTEN nuclear translocation: Importin-11 [<xref ref-type="bibr" rid="B194-cancers-11-01247">194</xref>], Ndfip1 [<xref ref-type="bibr" rid="B195-cancers-11-01247">195</xref>], Grb2 [<xref ref-type="bibr" rid="B196-cancers-11-01247">196</xref>], ATM [<xref ref-type="bibr" rid="B197-cancers-11-01247">197</xref>], PERK [<xref ref-type="bibr" rid="B193-cancers-11-01247">193</xref>], SDHD [<xref ref-type="bibr" rid="B198-cancers-11-01247">198</xref>], Rab5/Ndfip1 [<xref ref-type="bibr" rid="B199-cancers-11-01247">199</xref>], PNUTS [<xref ref-type="bibr" rid="B200-cancers-11-01247">200</xref>], LKB-1 [<xref ref-type="bibr" rid="B201-cancers-11-01247">201</xref>], oxidative stress [<xref ref-type="bibr" rid="B202-cancers-11-01247">202</xref>], and Ran [<xref ref-type="bibr" rid="B188-cancers-11-01247">188</xref>]. [<xref ref-type="bibr" rid="B149-cancers-11-01247">149</xref>], acid ceramidase [<xref ref-type="bibr" rid="B203-cancers-11-01247">203</xref>], free fatty acid-induced oxidative stress [<xref ref-type="bibr" rid="B204-cancers-11-01247">204</xref>], genotoxic stress [<xref ref-type="bibr" rid="B49-cancers-11-01247">49</xref>], ΔNp63α [<xref ref-type="bibr" rid="B205-cancers-11-01247">205</xref>,<xref ref-type="bibr" rid="B206-cancers-11-01247">206</xref>], NPM1 [<xref ref-type="bibr" rid="B207-cancers-11-01247">207</xref>], and ATP [<xref ref-type="bibr" rid="B208-cancers-11-01247">208</xref>]. In contrast, the following factors cause PTEN depletion in the nucleus: BCR-ABL Based on the reported roles of these factors in tumorigenesis, nuclear PTEN has been implicated to play an anti-tumorigenic role, but this role is very likely to be tumor type and stage specific. For example, in glioblastoma multiforme, <italic>PTEN</italic> mutations—such as K13E, L320S, and T277A—reduce nuclear accumulation of PTEN [<xref ref-type="bibr" rid="B209-cancers-11-01247">209</xref>]. More suggestive in human chronic myeloid leukemia is BCR-ABL, which promotes PTEN exclusion [<xref ref-type="bibr" rid="B210-cancers-11-01247">210</xref>]. As the functions of PTEN in the cell nucleus are phosphatase independent, its role in conferring genome stability may be important in its tumor-suppressive functions.</p>
</sec>
</sec>
<sec id="sec6-cancers-11-01247" sec-type="conclusions">
<title>6. Conclusions</title>
<p>This review highlights the latest findings of multifaceted mechanisms in regulating PTEN functions. However, there are still considerable number of unresolved questions. For example, how the diverse subcellular functions of PTEN are being coordinated? Similarly, what is the relative contribution to individual cancer hallmarks from the loss of PTEN functions in the cytoplasm, nucleus, and other subcellular organelles during tumor progression? Also, is there crosstalk between different PTMs of PTEN and how they are regulated? From a translational standpoint, a significant fraction of human tumors still harbors a wild-type copy of <italic>PTEN</italic>. The possibility of enhancing its expression or catalytic activity will be an area of future research. In summary, a full understanding of the regulatory mechanisms of this key tumor suppressor may guide the future development of more effective therapeutics to restore PTEN anti-tumor activities.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>All of the authors contributed to writing the article.</p>
</notes>
<notes>
<title>Funding</title>
<p>Lo Kwee-Seong Biomedical Research Seed Fund, 6903806, and Pilot Project Fund, 4930742/4930783, from the Brain and Mind Institute of the Chinese University of Hong Kong; Collaborative Research Fund grants, C4014-14G, from the Hong Kong University Grants Committee.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">4EBP1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">4E-binding protein 1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AMD1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">S-adenosylmethionine decarboxylase 1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ATM</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ataxia telangiectasia mutated</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ATP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Adenosine triphosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BCR-ABL </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Breakpoint cluster region-Abelson</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">C </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Carboxyl </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Ca<sup>2+</sup>
</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Calcium </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CBR1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ca<sup>2+</sup>-binding region 1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cdh1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cadherin-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CDK1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cyclin D1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CHIP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">C-terminus of Hsc70-interacting protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CKII </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Casein kinase II </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">COSMIC </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Catalogue of Somatic Mutations In Cancer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">cPLA2 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phospholipase A2 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DSP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Dual-specificity phosphatase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ER </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Endoplasmic reticulum</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FOXO3a </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Forkhead box protein O3a </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FOXO1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Forkhead box protein O1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GLUT4 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Glucose transporter type 4 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Grb2 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Growth factor receptor-bound protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GSK-3β </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Glycogen synthase kinase 3 beta </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HAUSP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Herpesvirus-associated ubiquitin-specific protease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LKB-1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Liver kinase B-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LncRNAs</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Long-noncoding RNAs </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LRR </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Leucine rich repeat</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MAPK </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Mitogen-activated protein kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">miRNAs </td>
<td align="left" colspan="1" rowspan="1" valign="middle">MicroRNAs </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ms</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Millisecond</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">N </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Amino </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ncRNAs </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Noncoding RNAs </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Ndfip1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">NEDD4 family-interacting protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Ndfip1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">NEDD4 family-interacting protein 1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NEDD4-1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Developmentally down-regulated protein 4-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NPM-1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nucleophosmin-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">OTUD3 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ovarian tumor domain-containing protein 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PBM </td>
<td align="left" colspan="1" rowspan="1" valign="middle">PIP2-binding motif </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PDZ</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Postsynaptic density protein-<italic>Drosophila</italic> disc large tumor suppressor-Zonula occludens-1 protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PDZ-BM </td>
<td align="left" colspan="1" rowspan="1" valign="middle">PDZ-binding motif </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PERK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein kinase R-like endoplasmic reticulum kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PEST </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Proline, glutamate, serine, threonine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PI(5)P</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol 5-monophosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PI3K </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphoinositide 3-kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PIASX </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein Inhibitor of Activated STAT2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PIP2/PI(4,5)P2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol 4,5-bisphosphate </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PIP3 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">3′ phosphate of phosphatidylinositol 3,4,5-triphosphate </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PKCδ </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein kinase Cδ</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PLCδ1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phospholipase C δ1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PNUTS </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein phosphatase nuclear targeting subunit</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">POPC </td>
<td align="left" colspan="1" rowspan="1" valign="middle">1-palmitoyl-2-oleoyl-glycero-3-phosphocholine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">POPCS </td>
<td align="left" colspan="1" rowspan="1" valign="middle">1-palmitoyl-2-oleoyl-glycero-3-phosphoserine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPARγ </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Proliferator-activated receptor-γ </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PRKN </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Parkin RBR E3 ubiquitin protein ligase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PTEN </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatase and tensin homolog deleted on chromosome 10 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PTEN-L </td>
<td align="left" colspan="1" rowspan="1" valign="middle">PTEN-long</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PTENP1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">PTEN pseudogene 1 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PTP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein tyrosine phosphatase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SDHD </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Succinate dehydrogenase complex subunit D</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SREBP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sterol regulatory element-binding proteins </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TCGA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">The Cancer Genome Atlas </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TOP2A </td>
<td align="left" colspan="1" rowspan="1" valign="middle">DNA topoisomerase-2 alpha </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">USP11 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Ubiquitin specific peptidase 11</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">VEGF </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Vascular endothelial growth factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">WHSC1 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Wolf–Hirschhorn syndrome candidate 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">WWP2 </td>
<td align="left" colspan="1" rowspan="1" valign="middle">WW domain-containing protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">XIAP </td>
<td align="left" colspan="1" rowspan="1" valign="middle">X-linked inhibitor of apoptosis</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-cancers-11-01247">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta</article-title>
<source/>Cancer Res.
          <year>1997</year>
<volume>57</volume>
<fpage>2124</fpage>
<lpage>2129</lpage>
<pub-id pub-id-type="pmid">9187108</pub-id>
</element-citation>
</ref>
<ref id="B2-cancers-11-01247">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liaw</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Podsypanina</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Puc</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miliaresis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rodgers</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>McCombie</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</article-title>
<source/>Science
          <year>1997</year>
<volume>275</volume>
<fpage>1943</fpage>
<lpage>1947</lpage>
<pub-id pub-id-type="doi">10.1126/science.275.5308.1943</pub-id>
<pub-id pub-id-type="pmid">9072974</pub-id>
</element-citation>
</ref>
<ref id="B3-cancers-11-01247">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steck</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Pershouse</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Jasser</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ligon</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Langford</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Baumgard</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Hattier</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers</article-title>
<source/>Nat. Genet.
          <year>1997</year>
<volume>15</volume>
<fpage>356</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1038/ng0497-356</pub-id>
<pub-id pub-id-type="pmid">9090379</pub-id>
</element-citation>
</ref>
<ref id="B4-cancers-11-01247">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>I.U.</given-names>
</name>
<name>
<surname>Schriml</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity</article-title>
<source/>J. Natl. Cancer Inst.
          <year>1999</year>
<volume>91</volume>
<fpage>1922</fpage>
<lpage>1932</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/91.22.1922</pub-id>
<pub-id pub-id-type="pmid">10564676</pub-id>
</element-citation>
</ref>
<ref id="B5-cancers-11-01247">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>I.U.</given-names>
</name>
</person-group>
<article-title>Gatekeeper for endometrium: The PTEN tumor suppressor gene</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2000</year>
<volume>92</volume>
<fpage>861</fpage>
<lpage>863</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/92.11.861</pub-id>
<pub-id pub-id-type="pmid">10841815</pub-id>
</element-citation>
</ref>
<ref id="B6-cancers-11-01247">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwabi-Addo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Podsypanina</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ittmann</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>11563</fpage>
<lpage>11568</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.201167798</pub-id>
<pub-id pub-id-type="pmid">11553783</pub-id>
</element-citation>
</ref>
<ref id="B7-cancers-11-01247">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trotman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Niki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dotan</surname>
<given-names>Z.A.</given-names>
</name>
<name>
<surname>Koutcher</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Di Cristofano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khoo</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Roy-Burman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Van Dyke</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pten dose dictates cancer progression in the prostate</article-title>
<source/>PLoS Biol.
          <year>2003</year>
<volume>1</volume>
<elocation-id>E59</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pbio.0000059</pub-id>
<pub-id pub-id-type="pmid">14691534</pub-id>
</element-citation>
</ref>
<ref id="B8-cancers-11-01247">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Regulation of PTEN expression by noncoding RNAs</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2018</year>
<volume>37</volume>
<fpage>223</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-018-0898-9</pub-id>
<pub-id pub-id-type="pmid">30217221</pub-id>
</element-citation>
</ref>
<ref id="B9-cancers-11-01247">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poliseno</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>PTEN ceRNA networks in human cancer</article-title>
<source/>Methods
          <year>2015</year>
<volume>77–78</volume>
<fpage>41</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymeth.2015.01.013</pub-id>
</element-citation>
</ref>
<ref id="B10-cancers-11-01247">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate</article-title>
<source/>J. Biol. Chem.
          <year>2003</year>
<volume>278</volume>
<fpage>33617</fpage>
<lpage>33620</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.C300296200</pub-id>
<pub-id pub-id-type="pmid">12857747</pub-id>
</element-citation>
</ref>
<ref id="B11-cancers-11-01247">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tibarewal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zilidis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Spinelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schurch</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Maccario</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity</article-title>
<source/>Sci. Signal.
          <year>2012</year>
<volume>5</volume>
<fpage>ra18</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.2002138</pub-id>
<pub-id pub-id-type="pmid">22375056</pub-id>
</element-citation>
</ref>
<ref id="B12-cancers-11-01247">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>The functions and regulation of the PTEN tumour suppressor: New modes and prospects</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2018</year>
<volume>19</volume>
<fpage>547</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="doi">10.1038/s41580-018-0015-0</pub-id>
<pub-id pub-id-type="pmid">29858604</pub-id>
</element-citation>
</ref>
<ref id="B13-cancers-11-01247">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fruman</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Bagrodia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>The PI3K Pathway in Human Disease</article-title>
<source/>Cell
          <year>2017</year>
<volume>170</volume>
<fpage>605</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.07.029</pub-id>
<pub-id pub-id-type="pmid">28802037</pub-id>
</element-citation>
</ref>
<ref id="B14-cancers-11-01247">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.O.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Georgescu</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Di Cristofano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maehama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pavletich</surname>
<given-names>N.P.</given-names>
</name>
</person-group>
<article-title>Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association</article-title>
<source/>Cell
          <year>1999</year>
<volume>99</volume>
<fpage>323</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81663-3</pub-id>
<pub-id pub-id-type="pmid">10555148</pub-id>
</element-citation>
</ref>
<ref id="B15-cancers-11-01247">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Membrane-binding and activation mechanism of PTEN</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2003</year>
<volume>100</volume>
<fpage>7491</fpage>
<lpage>7496</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0932835100</pub-id>
<pub-id pub-id-type="pmid">12808147</pub-id>
</element-citation>
</ref>
<ref id="B16-cancers-11-01247">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fragoso</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Barata</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Kinases, tails and more: Regulation of PTEN function by phosphorylation</article-title>
<source/>Methods
          <year>2015</year>
<volume>77–78</volume>
<fpage>75</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymeth.2014.10.015</pub-id>
</element-citation>
</ref>
<ref id="B17-cancers-11-01247">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sotelo</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Schepens</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Valiente</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hendriks</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Pulido</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>PTEN-PDZ domain interactions: Binding of PTEN to PDZ domains of PTPN13</article-title>
<source/>Methods
          <year>2015</year>
<volume>77–78</volume>
<fpage>147</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymeth.2014.10.017</pub-id>
</element-citation>
</ref>
<ref id="B18-cancers-11-01247">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaquero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nguyen Ho-Bouldoires</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Claperon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fouassier</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: From signaling regulation to clinical relevance</article-title>
<source/>Oncogene
          <year>2017</year>
<volume>36</volume>
<fpage>3067</fpage>
<lpage>3079</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2016.462</pub-id>
<pub-id pub-id-type="pmid">28068322</pub-id>
</element-citation>
</ref>
<ref id="B19-cancers-11-01247">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haynie</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Superdomains in the protein structure hierarchy: The case of PTP-C2</article-title>
<source/>Protein Sci.
          <year>2015</year>
<volume>24</volume>
<fpage>874</fpage>
<lpage>882</lpage>
<pub-id pub-id-type="doi">10.1002/pro.2664</pub-id>
<pub-id pub-id-type="pmid">25694109</pub-id>
</element-citation>
</ref>
<ref id="B20-cancers-11-01247">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rodriguez-Escudero</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Stumpf</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Molina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cid</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Pulido</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A functional dissection of PTEN N-terminus: Implications in PTEN subcellular targeting and tumor suppressor activity</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0119287</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0119287</pub-id>
<pub-id pub-id-type="pmid">25875300</pub-id>
</element-citation>
</ref>
<ref id="B21-cancers-11-01247">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duerr</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Rollbrocker</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Meyer-Puttlitz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Schramm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wiestler</surname>
<given-names>O.D.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN mutations in gliomas and glioneuronal tumors</article-title>
<source/>Oncogene
          <year>1998</year>
<volume>16</volume>
<fpage>2259</fpage>
<lpage>2264</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1201756</pub-id>
<pub-id pub-id-type="pmid">9619835</pub-id>
</element-citation>
</ref>
<ref id="B22-cancers-11-01247">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trotman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Alimonti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Teruya-Feldstein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pavletich</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>Carver</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Cordon-Cardo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Erdjument-Bromage</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ubiquitination regulates PTEN nuclear import and tumor suppression</article-title>
<source/>Cell
          <year>2007</year>
<volume>128</volume>
<fpage>141</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.11.040</pub-id>
<pub-id pub-id-type="pmid">17218261</pub-id>
</element-citation>
</ref>
<ref id="B23-cancers-11-01247">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radivojac</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vacic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Haynes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cocklin</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Mohan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heyen</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Goebl</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Iakoucheva</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Identification, analysis, and prediction of protein ubiquitination sites</article-title>
<source/>Proteins
          <year>2010</year>
<volume>78</volume>
<fpage>365</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1002/prot.22555</pub-id>
<pub-id pub-id-type="pmid">19722269</pub-id>
</element-citation>
</ref>
<ref id="B24-cancers-11-01247">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denning</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jean-Joseph</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Durden</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth</article-title>
<source/>Oncogene
          <year>2007</year>
<volume>26</volume>
<fpage>3930</fpage>
<lpage>3940</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1210175</pub-id>
<pub-id pub-id-type="pmid">17213812</pub-id>
</element-citation>
</ref>
<ref id="B25-cancers-11-01247">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>TPIP: A novel phosphoinositide 3-phosphatase</article-title>
<source/>Biochem. J.
          <year>2001</year>
<volume>360</volume>
<fpage>277</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1042/bj3600277</pub-id>
<pub-id pub-id-type="pmid">11716755</pub-id>
</element-citation>
</ref>
<ref id="B26-cancers-11-01247">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furnari</surname>
<given-names>F.B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Cavenee</surname>
<given-names>W.K.</given-names>
</name>
</person-group>
<article-title>The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells</article-title>
<source/>Cancer Res.
          <year>1998</year>
<volume>58</volume>
<fpage>5002</fpage>
<lpage>5008</lpage>
<pub-id pub-id-type="pmid">9823298</pub-id>
</element-citation>
</ref>
<ref id="B27-cancers-11-01247">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maccario</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Spinelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tibarewal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Glancy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Weijer</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>C.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN</article-title>
<source/>Oncogene
          <year>2010</year>
<volume>29</volume>
<fpage>687</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2009.384</pub-id>
<pub-id pub-id-type="pmid">19915616</pub-id>
</element-citation>
</ref>
<ref id="B28-cancers-11-01247">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>Mechanics of membrane fusion</article-title>
<source/>Nat. Struct. Biol.
          <year>1998</year>
<volume>5</volume>
<fpage>839</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="doi">10.1038/2280</pub-id>
<pub-id pub-id-type="pmid">9783736</pub-id>
</element-citation>
</ref>
<ref id="B29-cancers-11-01247">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbalan-Garcia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gomez-Fernandez</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Signaling through C2 domains: More than one lipid target</article-title>
<source/>Biochim. Biophys. Acta
          <year>2014</year>
<volume>1838</volume>
<fpage>1536</fpage>
<lpage>1547</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamem.2014.01.008</pub-id>
<pub-id pub-id-type="pmid">24440424</pub-id>
</element-citation>
</ref>
<ref id="B30-cancers-11-01247">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Post-translational modifications of PTEN and their potential therapeutic implications</article-title>
<source/>Curr. Cancer Drug Targets
          <year>2011</year>
<volume>11</volume>
<fpage>536</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="doi">10.2174/156800911795655930</pub-id>
<pub-id pub-id-type="pmid">21486223</pub-id>
</element-citation>
</ref>
<ref id="B31-cancers-11-01247">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalyoncu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Keskin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gursoy</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Interaction prediction and classification of PDZ domains</article-title>
<source/>BMC Bioinform.
          <year>2010</year>
<volume>11</volume>
<elocation-id>357</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2105-11-357</pub-id>
</element-citation>
</ref>
<ref id="B32-cancers-11-01247">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luck</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Charbonnier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trave</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The emerging contribution of sequence context to the specificity of protein interactions mediated by PDZ domains</article-title>
<source/>FEBS Lett.
          <year>2012</year>
<volume>586</volume>
<fpage>2648</fpage>
<lpage>2661</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2012.03.056</pub-id>
<pub-id pub-id-type="pmid">22709956</pub-id>
</element-citation>
</ref>
<ref id="B33-cancers-11-01247">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2009</year>
<volume>10</volume>
<fpage>87</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2540</pub-id>
<pub-id pub-id-type="pmid">19153575</pub-id>
</element-citation>
</ref>
<ref id="B34-cancers-11-01247">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chaffotte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lafage</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Prehaud</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cordier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Simenel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Delepierre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buc</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lafon</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interference with the PTEN-MAST2 interaction by a viral protein leads to cellular relocalization of PTEN</article-title>
<source/>Sci. Signal.
          <year>2012</year>
<volume>5</volume>
<fpage>ra58</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.2002941</pub-id>
<pub-id pub-id-type="pmid">22894835</pub-id>
</element-citation>
</ref>
<ref id="B35-cancers-11-01247">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazquez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Yanagida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Devreotes</surname>
<given-names>P.N.</given-names>
</name>
</person-group>
<article-title>Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2006</year>
<volume>103</volume>
<fpage>3633</fpage>
<lpage>3638</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0510570103</pub-id>
<pub-id pub-id-type="pmid">16537447</pub-id>
</element-citation>
</ref>
<ref id="B36-cancers-11-01247">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franke</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Hornik</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Segev</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shostak</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>PI3K/Akt and apoptosis: Size matters</article-title>
<source/>Oncogene
          <year>2003</year>
<volume>22</volume>
<fpage>8983</fpage>
<lpage>8998</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1207115</pub-id>
<pub-id pub-id-type="pmid">14663477</pub-id>
</element-citation>
</ref>
<ref id="B37-cancers-11-01247">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christie</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Zochodne</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Peripheral Axon Regrowth: New Molecular Approaches</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>240</volume>
<fpage>310</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.02.059</pub-id>
<pub-id pub-id-type="pmid">23500101</pub-id>
</element-citation>
</ref>
<ref id="B38-cancers-11-01247">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis</article-title>
<source/>Cancer Res.
          <year>2005</year>
<volume>65</volume>
<fpage>8096</fpage>
<lpage>8100</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1888</pub-id>
<pub-id pub-id-type="pmid">16166282</pub-id>
</element-citation>
</ref>
<ref id="B39-cancers-11-01247">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>L.C.</given-names>
</name>
</person-group>
<article-title>AKT/PKB signaling: Navigating downstream</article-title>
<source/>Cell
          <year>2007</year>
<volume>129</volume>
<fpage>1261</fpage>
<lpage>1274</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id>
<pub-id pub-id-type="pmid">17604717</pub-id>
</element-citation>
</ref>
<ref id="B40-cancers-11-01247">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Salmena</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>The functions and regulation of the PTEN tumour suppressor</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2012</year>
<volume>13</volume>
<fpage>283</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3330</pub-id>
<pub-id pub-id-type="pmid">22473468</pub-id>
</element-citation>
</ref>
<ref id="B41-cancers-11-01247">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gimm</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Perren</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Ziebold</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hinze</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Delbridge</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>J.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors</article-title>
<source/>Am. J. Pathol.
          <year>2000</year>
<volume>156</volume>
<fpage>1693</fpage>
<lpage>1700</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)65040-7</pub-id>
<pub-id pub-id-type="pmid">10793080</pub-id>
</element-citation>
</ref>
<ref id="B42-cancers-11-01247">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.S.</given-names>
</name>
<name>
<surname>Langford</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Koul</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bondy</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Y.K.</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>W.K.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis</article-title>
<source/>Cancer Res.
          <year>1999</year>
<volume>59</volume>
<fpage>1820</fpage>
<lpage>1824</lpage>
<pub-id pub-id-type="pmid">10213484</pub-id>
</element-citation>
</ref>
<ref id="B43-cancers-11-01247">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteman</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Pavey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>N.K.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma</article-title>
<source/>Int. J. Cancer
          <year>2002</year>
<volume>99</volume>
<fpage>63</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.10294</pub-id>
<pub-id pub-id-type="pmid">11948493</pub-id>
</element-citation>
</ref>
<ref id="B44-cancers-11-01247">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCall</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Witton</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Grimsley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Is PTEN loss associated with clinical outcome measures in human prostate cancer?</article-title>
<source/>Brit. J. Cancer
          <year>2008</year>
<volume>99</volume>
<fpage>1296</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6604680</pub-id>
<pub-id pub-id-type="pmid">18854827</pub-id>
</element-citation>
</ref>
<ref id="B45-cancers-11-01247">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fei</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Greshock</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bachman</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C.Y.</given-names>
</name>
</person-group>
<article-title>Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma</article-title>
<source/>Exp. Ther. Med.
          <year>2013</year>
<volume>5</volume>
<fpage>57</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.3892/etm.2012.749</pub-id>
<pub-id pub-id-type="pmid">23251242</pub-id>
</element-citation>
</ref>
<ref id="B46-cancers-11-01247">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puc</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Keniry</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Pandita</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Memeo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mansukhani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Murty</surname>
<given-names>V.V.V.S.</given-names>
</name>
<name>
<surname>Gaciong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Meek</surname>
<given-names>S.E.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lack of PTEN sequesters CHK1 and initiates genetic instability</article-title>
<source/>Cancer Cell
          <year>2005</year>
<volume>7</volume>
<fpage>193</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccr.2005.01.009</pub-id>
<pub-id pub-id-type="pmid">15710331</pub-id>
</element-citation>
</ref>
<ref id="B47-cancers-11-01247">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Balajee</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.X.</given-names>
</name>
</person-group>
<article-title>Essential role for nuclear PTEN in maintaining chromosomal integrity</article-title>
<source/>Cell
          <year>2007</year>
<volume>128</volume>
<fpage>157</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.11.042</pub-id>
<pub-id pub-id-type="pmid">17218262</pub-id>
</element-citation>
</ref>
<ref id="B48-cancers-11-01247">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>S.Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.X.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
</person-group>
<article-title>PTEN regulates PLK1 and controls chromosomal stability during cell division</article-title>
<source/>Cell Cycle
          <year>2016</year>
<volume>15</volume>
<fpage>2476</fpage>
<lpage>2485</lpage>
<pub-id pub-id-type="doi">10.1080/15384101.2016.1203493</pub-id>
<pub-id pub-id-type="pmid">27398835</pub-id>
</element-citation>
</ref>
<ref id="B49-cancers-11-01247">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Srikumar</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>R.J.O.</given-names>
</name>
<name>
<surname>Gorrini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Raught</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Stambolic</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress</article-title>
<source/>Science
          <year>2013</year>
<volume>341</volume>
<fpage>395</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1126/science.1236188</pub-id>
<pub-id pub-id-type="pmid">23888040</pub-id>
</element-citation>
</ref>
<ref id="B50-cancers-11-01247">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandmaier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>S.Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
</person-group>
<article-title>Cell Cycle Control by PTEN</article-title>
<source/>J. Mol. Biol.
          <year>2017</year>
<volume>429</volume>
<fpage>2265</fpage>
<lpage>2277</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2017.06.004</pub-id>
<pub-id pub-id-type="pmid">28602818</pub-id>
</element-citation>
</ref>
<ref id="B51-cancers-11-01247">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Piluso</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Mechanistic insights into maintenance of high p53 acetylation by PTEN</article-title>
<source/>Mol. Cell
          <year>2006</year>
<volume>23</volume>
<fpage>575</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2006.06.028</pub-id>
<pub-id pub-id-type="pmid">16916644</pub-id>
</element-citation>
</ref>
<ref id="B52-cancers-11-01247">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer</article-title>
<source/>Oncogene
          <year>2016</year>
<volume>35</volume>
<fpage>251</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2015.80</pub-id>
<pub-id pub-id-type="pmid">25823029</pub-id>
</element-citation>
</ref>
<ref id="B53-cancers-11-01247">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.X.</given-names>
</name>
<name>
<surname>Lamb</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.X.</given-names>
</name>
</person-group>
<article-title>PTEN stabilizes TOP2A and regulates the DNA decatenation</article-title>
<source/>Sci. Rep.
          <year>2015</year>
<volume>5</volume>
<fpage>17873</fpage>
<pub-id pub-id-type="doi">10.1038/srep17873</pub-id>
<pub-id pub-id-type="pmid">26657567</pub-id>
</element-citation>
</ref>
<ref id="B54-cancers-11-01247">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bononi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Missiroli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Pinton</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Identification of PTEN at the ER and MAMs and its regulation of Ca<sup>2+</sup> signaling and apoptosis in a protein phosphatase-dependent manner</article-title>
<source/>Cell Death Differ.
          <year>2013</year>
<volume>20</volume>
<fpage>1631</fpage>
<lpage>1643</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2013.77</pub-id>
<pub-id pub-id-type="pmid">23811847</pub-id>
</element-citation>
</ref>
<ref id="B55-cancers-11-01247">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuchay</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Simoneschi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pagan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Missiroli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saraf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Florens</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Washburn</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Collazo-Lorduy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castillo-Martin</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth</article-title>
<source/>Nature
          <year>2017</year>
<volume>546</volume>
<fpage>554</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.1038/nature22965</pub-id>
<pub-id pub-id-type="pmid">28614300</pub-id>
</element-citation>
</ref>
<ref id="B56-cancers-11-01247">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hoell</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ahlemeyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Krieglstein</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>PTEN: A crucial mediator of mitochondria-dependent apoptosis</article-title>
<source/>Apoptosis
          <year>2006</year>
<volume>11</volume>
<fpage>197</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1007/s10495-006-3714-5</pub-id>
<pub-id pub-id-type="pmid">16502258</pub-id>
</element-citation>
</ref>
<ref id="B57-cancers-11-01247">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pretis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Buso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mavelli</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Mitochondrial energy metabolism and signalling in human glioblastoma cell lines with different PTEN gene status</article-title>
<source/>J. Bioenerg. Biomembr.
          <year>2018</year>
<volume>50</volume>
<fpage>33</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1007/s10863-017-9737-5</pub-id>
<pub-id pub-id-type="pmid">29209894</pub-id>
</element-citation>
</ref>
<ref id="B58-cancers-11-01247">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.G.</given-names>
</name>
</person-group>
<article-title>Identification of nucleolus-localized PTEN and its function in regulating ribosome biogenesis</article-title>
<source/>Mol. Biol. Rep.
          <year>2014</year>
<volume>41</volume>
<fpage>6383</fpage>
<lpage>6390</lpage>
<pub-id pub-id-type="doi">10.1007/s11033-014-3518-6</pub-id>
<pub-id pub-id-type="pmid">24969487</pub-id>
</element-citation>
</ref>
<ref id="B59-cancers-11-01247">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derenzini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montanaro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Trere</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Ribosome biogenesis and cancer</article-title>
<source/>Acta Histochem.
          <year>2017</year>
<volume>119</volume>
<fpage>190</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1016/j.acthis.2017.01.009</pub-id>
<pub-id pub-id-type="pmid">28168996</pub-id>
</element-citation>
</ref>
<ref id="B60-cancers-11-01247">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McNutt</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.X.</given-names>
</name>
</person-group>
<article-title>PTEN beta is an alternatively translated isoform of PTEN that regulates rDNA transcription</article-title>
<source/>Nat. Commun.
          <year>2017</year>
<volume>8</volume>
<fpage>14771</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms14771</pub-id>
<pub-id pub-id-type="pmid">28332494</pub-id>
</element-citation>
</ref>
<ref id="B61-cancers-11-01247">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Ree</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Jeganathan</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Kanakkanthara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>van Deursen</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes</article-title>
<source/>Nat. Cell Biol.
          <year>2016</year>
<volume>18</volume>
<fpage>814</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1038/ncb3369</pub-id>
<pub-id pub-id-type="pmid">27240320</pub-id>
</element-citation>
</ref>
<ref id="B62-cancers-11-01247">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shnitsar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bashkurov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Masson</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Ogunjimi</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Mosessian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cabeza</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Trcka</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gish</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN regulates cilia through Dishevelled</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>8388</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms9388</pub-id>
<pub-id pub-id-type="pmid">26399523</pub-id>
</element-citation>
</ref>
<ref id="B63-cancers-11-01247">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopkins</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Fine</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Steinbach</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dendy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pappas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Hodakoski</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mense</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival</article-title>
<source/>Science
          <year>2013</year>
<volume>341</volume>
<fpage>399</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1126/science.1234907</pub-id>
<pub-id pub-id-type="pmid">23744781</pub-id>
</element-citation>
</ref>
<ref id="B64-cancers-11-01247">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>McNutt</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTENalpha, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism</article-title>
<source/>Cell Metab.
          <year>2014</year>
<volume>19</volume>
<fpage>836</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2014.03.023</pub-id>
<pub-id pub-id-type="pmid">24768297</pub-id>
</element-citation>
</ref>
<ref id="B65-cancers-11-01247">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Putz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Howitt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Doan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Silke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells</article-title>
<source/>Sci. Signal.
          <year>2012</year>
<volume>5</volume>
<fpage>ra70</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.2003084</pub-id>
<pub-id pub-id-type="pmid">23012657</pub-id>
</element-citation>
</ref>
<ref id="B66-cancers-11-01247">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN-L promotes type I interferon responses and antiviral immunity</article-title>
<source/>Cell. Mol. Immunol.
          <year>2018</year>
<volume>15</volume>
<fpage>48</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1038/cmi.2017.102</pub-id>
<pub-id pub-id-type="pmid">29057971</pub-id>
</element-citation>
</ref>
<ref id="B67-cancers-11-01247">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goncalves</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Malmqvist</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hubens</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Grist</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hobbs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Trigo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Risling</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Angeria</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Damberg</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal RAR beta Signaling Modulates PTEN Activity Directly in Neurons and via Exosome Transfer in Astrocytes to Prevent Glial Scar Formation and Induce Spinal Cord Regeneration</article-title>
<source/>J. Neurosci.
          <year>2015</year>
<volume>35</volume>
<fpage>15731</fpage>
<lpage>15745</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1339-15.2015</pub-id>
<pub-id pub-id-type="pmid">26609164</pub-id>
</element-citation>
</ref>
<ref id="B68-cancers-11-01247">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Refael</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zelikovitch</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shalom</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Siegal</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades</article-title>
<source/>Neuro Oncol.
          <year>2010</year>
<volume>12</volume>
<fpage>173</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1093/neuonc/nop041</pub-id>
<pub-id pub-id-type="pmid">20150384</pub-id>
</element-citation>
</ref>
<ref id="B69-cancers-11-01247">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Mattos-Arruda</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mayor</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>C.K.Y.</given-names>
</name>
<name>
<surname>Weigelt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martinez-Ricarte</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Torrejon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raventos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>8839</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms9839</pub-id>
<pub-id pub-id-type="pmid">26554728</pub-id>
</element-citation>
</ref>
<ref id="B70-cancers-11-01247">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>L.X.</given-names>
</name>
<name>
<surname>Bonora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salmena</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Hobbs</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Lunardi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>R.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function</article-title>
<source/>Cell
          <year>2014</year>
<volume>157</volume>
<fpage>595</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2014.03.027</pub-id>
<pub-id pub-id-type="pmid">24766807</pub-id>
</element-citation>
</ref>
<ref id="B71-cancers-11-01247">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamaspishvili</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Scher</surname>
<given-names>H.I.</given-names>
</name>
<name>
<surname>De Marzo</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Squire</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Lotan</surname>
<given-names>T.L.</given-names>
</name>
</person-group>
<article-title>Clinical implications of PTEN loss in prostate cancer</article-title>
<source/>Nat. Rev. Urol.
          <year>2018</year>
<volume>15</volume>
<fpage>222</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1038/nrurol.2018.9</pub-id>
<pub-id pub-id-type="pmid">29460925</pub-id>
</element-citation>
</ref>
<ref id="B72-cancers-11-01247">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McConechy</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheang</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Wiegand</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Senz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Use of mutation profiles to refine the classification of endometrial carcinomas</article-title>
<source/>J. Pathol.
          <year>2012</year>
<volume>228</volume>
<fpage>20</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1002/path.4056</pub-id>
<pub-id pub-id-type="pmid">22653804</pub-id>
</element-citation>
</ref>
<ref id="B73-cancers-11-01247">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Álvarez-Garcia</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tawil</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wise</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Mechanisms of PTEN loss in cancer: It’s all about diversity</article-title>
<source/>Semin. Cancer Biol.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2019.02.001</pub-id>
</element-citation>
</ref>
<ref id="B74-cancers-11-01247">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiencke</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jelluma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tihan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vandenberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tamguney</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Baumber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lamborn</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>M.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma</article-title>
<source/>Neuro Oncol.
          <year>2007</year>
<volume>9</volume>
<fpage>271</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1215/15228517-2007-003</pub-id>
<pub-id pub-id-type="pmid">17504928</pub-id>
</element-citation>
</ref>
<ref id="B75-cancers-11-01247">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roh</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Lauss</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flaherty</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rha</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival</article-title>
<source/>J. Investig. Dermatol.
          <year>2016</year>
<volume>136</volume>
<fpage>1002</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1016/j.jid.2016.01.024</pub-id>
<pub-id pub-id-type="pmid">26854490</pub-id>
</element-citation>
</ref>
<ref id="B76-cancers-11-01247">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Knudson</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>A continuum model for tumour suppression</article-title>
<source/>Nature
          <year>2011</year>
<volume>476</volume>
<fpage>163</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1038/nature10275</pub-id>
<pub-id pub-id-type="pmid">21833082</pub-id>
</element-citation>
</ref>
<ref id="B77-cancers-11-01247">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alimonti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carracedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Clohessy</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Nardella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Egia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salmena</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sampieri</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Haveman</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Brogi</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Subtle variations in Pten dose determine cancer susceptibility</article-title>
<source/>Nat. Genet.
          <year>2010</year>
<volume>42</volume>
<fpage>454</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.1038/ng.556</pub-id>
<pub-id pub-id-type="pmid">20400965</pub-id>
</element-citation>
</ref>
<ref id="B78-cancers-11-01247">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carracedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alimonti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>PTEN level in tumor suppression: How much is too little?</article-title>
<source/>Cancer Res.
          <year>2011</year>
<volume>71</volume>
<fpage>629</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2488</pub-id>
<pub-id pub-id-type="pmid">21266353</pub-id>
</element-citation>
</ref>
<ref id="B79-cancers-11-01247">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvesen</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Akslen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma</article-title>
<source/>Int. J. Cancer
          <year>2001</year>
<volume>91</volume>
<fpage>22</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1002/1097-0215(20010101)91:1&lt;22::AID-IJC1002&gt;3.0.CO;2-S</pub-id>
<pub-id pub-id-type="pmid">11149415</pub-id>
</element-citation>
</ref>
<ref id="B80-cancers-11-01247">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koul</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>PTEN signaling pathways in glioblastoma</article-title>
<source/>Cancer Biol. Ther.
          <year>2008</year>
<volume>7</volume>
<fpage>1321</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.7.9.6954</pub-id>
<pub-id pub-id-type="pmid">18836294</pub-id>
</element-citation>
</ref>
<ref id="B81-cancers-11-01247">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soria</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Issa</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Kurie</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Khuri</surname>
<given-names>F.R.</given-names>
</name>
</person-group>
<article-title>Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation</article-title>
<source/>Clin. Cancer Res.
          <year>2002</year>
<volume>8</volume>
<fpage>1178</fpage>
<lpage>1184</lpage>
<pub-id pub-id-type="pmid">12006535</pub-id>
</element-citation>
</ref>
<ref id="B82-cancers-11-01247">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Post-translational regulation of PTEN</article-title>
<source/>Oncogene
          <year>2008</year>
<volume>27</volume>
<fpage>5454</fpage>
<lpage>5463</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2008.242</pub-id>
<pub-id pub-id-type="pmid">18794880</pub-id>
</element-citation>
</ref>
<ref id="B83-cancers-11-01247">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carver</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gopalan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carracedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alimonti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nardella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Varmeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Scardino</surname>
<given-names>P.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate</article-title>
<source/>Nat. Genet.
          <year>2009</year>
<volume>41</volume>
<fpage>619</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1038/ng.370</pub-id>
<pub-id pub-id-type="pmid">19396168</pub-id>
</element-citation>
</ref>
<ref id="B84-cancers-11-01247">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Joshua</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Cunha</surname>
<given-names>I.W.</given-names>
</name>
<name>
<surname>Coudry</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Ludkovski</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zielenska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Squire</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome</article-title>
<source/>Mod. Pathol.
          <year>2008</year>
<volume>21</volume>
<fpage>1451</fpage>
<lpage>1460</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.2008.96</pub-id>
<pub-id pub-id-type="pmid">18500259</pub-id>
</element-citation>
</ref>
<ref id="B85-cancers-11-01247">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krohn</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Freudenthaler</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Harasimowicz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kluth</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Burkhardt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tsourlakis</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tennstedt</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer</article-title>
<source/>Mod. Pathol.
          <year>2014</year>
<volume>27</volume>
<fpage>1612</fpage>
<lpage>1620</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.2014.70</pub-id>
<pub-id pub-id-type="pmid">24762546</pub-id>
</element-citation>
</ref>
<ref id="B86-cancers-11-01247">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wongvipat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hieronymus</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Carver</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Couto</surname>
<given-names>S.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis</article-title>
<source/>Nat. Genet.
          <year>2009</year>
<volume>41</volume>
<fpage>524</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="doi">10.1038/ng.371</pub-id>
<pub-id pub-id-type="pmid">19396167</pub-id>
</element-citation>
</ref>
<ref id="B87-cancers-11-01247">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.B.</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Dotan</surname>
<given-names>Z.A.</given-names>
</name>
<name>
<surname>Niki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koutcher</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Scher</surname>
<given-names>H.I.</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gerald</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis</article-title>
<source/>Nature
          <year>2005</year>
<volume>436</volume>
<fpage>725</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="doi">10.1038/nature03918</pub-id>
<pub-id pub-id-type="pmid">16079851</pub-id>
</element-citation>
</ref>
<ref id="B88-cancers-11-01247">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayo</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Donner</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network</article-title>
<source/>Trends Biochem. Sci.
          <year>2002</year>
<volume>27</volume>
<fpage>462</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0004(02)02166-7</pub-id>
<pub-id pub-id-type="pmid">12217521</pub-id>
</element-citation>
</ref>
<ref id="B89-cancers-11-01247">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lesche</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Whale</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Martinez-Diaz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rozengurt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>R.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms</article-title>
<source/>Cancer Cell
          <year>2003</year>
<volume>3</volume>
<fpage>117</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/S1535-6108(03)00021-7</pub-id>
<pub-id pub-id-type="pmid">12620407</pub-id>
</element-citation>
</ref>
<ref id="B90-cancers-11-01247">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stambolic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>MacPherson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Snow</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Benchimol</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>Regulation of PTEN transcription by p53</article-title>
<source/>Mol. Cell
          <year>2001</year>
<volume>8</volume>
<fpage>317</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(01)00323-9</pub-id>
<pub-id pub-id-type="pmid">11545734</pub-id>
</element-citation>
</ref>
<ref id="B91-cancers-11-01247">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puszynski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hat</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lipniacki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Oscillations and bistability in the stochastic model of p53 regulation</article-title>
<source/>J. Theor. Biol.
          <year>2008</year>
<volume>254</volume>
<fpage>452</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="doi">10.1016/j.jtbi.2008.05.039</pub-id>
<pub-id pub-id-type="pmid">18577387</pub-id>
</element-citation>
</ref>
<ref id="B92-cancers-11-01247">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallia</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Rand</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Eberhart</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>S.K.N.</given-names>
</name>
<name>
<surname>Oba-Shinjo</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Carlotti</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Caballero</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>A.J.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PIK3CA gene mutations in pediatric and adult glioblastoma multiforme</article-title>
<source/>Mol. Cancer Res.
          <year>2006</year>
<volume>4</volume>
<fpage>709</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-06-0172</pub-id>
<pub-id pub-id-type="pmid">17050665</pub-id>
</element-citation>
</ref>
<ref id="B93-cancers-11-01247">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nishizuka</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Uesugi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sugai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Koeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer</article-title>
<source/>J. Surg. Res.
          <year>2017</year>
<volume>212</volume>
<fpage>195</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.jss.2017.01.018</pub-id>
<pub-id pub-id-type="pmid">28550907</pub-id>
</element-citation>
</ref>
<ref id="B94-cancers-11-01247">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>VanderLaan</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Rangachari</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mockus</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Spotlow</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Reddi</surname>
<given-names>H.V.</given-names>
</name>
<name>
<surname>Malcolm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huberman</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes</article-title>
<source/>Lung Cancer
          <year>2017</year>
<volume>106</volume>
<fpage>17</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.lungcan.2017.01.011</pub-id>
<pub-id pub-id-type="pmid">28285689</pub-id>
</element-citation>
</ref>
<ref id="B95-cancers-11-01247">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Toker</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>AKT/PKB Signaling: Navigating the Network</article-title>
<source/>Cell
          <year>2017</year>
<volume>169</volume>
<fpage>381</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.04.001</pub-id>
<pub-id pub-id-type="pmid">28431241</pub-id>
</element-citation>
</ref>
<ref id="B96-cancers-11-01247">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Senechal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Neshat</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Whang</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>Sawyers</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1998</year>
<volume>95</volume>
<fpage>15587</fpage>
<lpage>15591</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.26.15587</pub-id>
<pub-id pub-id-type="pmid">9861013</pub-id>
</element-citation>
</ref>
<ref id="B97-cancers-11-01247">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Datta</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Brunet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Cellular survival: A play in three Akts</article-title>
<source/>Genes Dev.
          <year>1999</year>
<volume>13</volume>
<fpage>2905</fpage>
<lpage>2927</lpage>
<pub-id pub-id-type="doi">10.1101/gad.13.22.2905</pub-id>
<pub-id pub-id-type="pmid">10579998</pub-id>
</element-citation>
</ref>
<ref id="B98-cancers-11-01247">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maroulakou</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Oemler</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Naber</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Tsichlis</surname>
<given-names>P.N.</given-names>
</name>
</person-group>
<article-title>Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/Neu and MMTV-polyoma middle T transgenic mice</article-title>
<source/>Cancer Res.
          <year>2007</year>
<volume>67</volume>
<fpage>167</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3782</pub-id>
<pub-id pub-id-type="pmid">17210696</pub-id>
</element-citation>
</ref>
<ref id="B99-cancers-11-01247">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Uhlmann</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo</article-title>
<source/>Cancer Res.
          <year>2004</year>
<volume>64</volume>
<fpage>7773</fpage>
<lpage>7779</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2487</pub-id>
<pub-id pub-id-type="pmid">15520182</pub-id>
</element-citation>
</ref>
<ref id="B100-cancers-11-01247">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottschalk</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Basila</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Brandts</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Stokoe</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Haas-Kogan</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>p27Kip1 is required for PTEN-induced G1 growth arrest</article-title>
<source/>Cancer Res.
          <year>2001</year>
<volume>61</volume>
<fpage>2105</fpage>
<lpage>2111</lpage>
<pub-id pub-id-type="pmid">11280773</pub-id>
</element-citation>
</ref>
<ref id="B101-cancers-11-01247">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seminario</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Precht</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wersto</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Gorospe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wange</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression</article-title>
<source/>Oncogene
          <year>2003</year>
<volume>22</volume>
<fpage>8195</fpage>
<lpage>8204</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1206872</pub-id>
<pub-id pub-id-type="pmid">14603260</pub-id>
</element-citation>
</ref>
<ref id="B102-cancers-11-01247">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Cristofano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Acetis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koff</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cordon-Cardo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse</article-title>
<source/>Nat. Genet.
          <year>2001</year>
<volume>27</volume>
<fpage>222</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1038/84879</pub-id>
<pub-id pub-id-type="pmid">11175795</pub-id>
</element-citation>
</ref>
<ref id="B103-cancers-11-01247">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomkiel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Saitoh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bernat</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Earnshaw</surname>
<given-names>W.C.</given-names>
</name>
</person-group>
<article-title>Cenp-C Is Required for Maintaining Proper Kinetochore Size and for a Timely Transition to Anaphase</article-title>
<source/>J. Cell Biol.
          <year>1994</year>
<volume>125</volume>
<fpage>531</fpage>
<lpage>545</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.125.3.531</pub-id>
<pub-id pub-id-type="pmid">8175879</pub-id>
</element-citation>
</ref>
<ref id="B104-cancers-11-01247">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Or</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Many</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Khoo</surname>
<given-names>U.S.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model</article-title>
<source/>Cancer Lett.
          <year>2018</year>
<volume>430</volume>
<fpage>67</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2018.05.012</pub-id>
<pub-id pub-id-type="pmid">29772266</pub-id>
</element-citation>
</ref>
<ref id="B105-cancers-11-01247">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>On the origin of cancer cells</article-title>
<source/>Science
          <year>1956</year>
<volume>123</volume>
<fpage>309</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id>
<pub-id pub-id-type="pmid">13298683</pub-id>
</element-citation>
</ref>
<ref id="B106-cancers-11-01247">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ortega-Molina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Efeyan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lopez-Guadamillas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Munoz-Martin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomez-Lopez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Canamero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mulero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romanos</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pten positively regulates brown adipose function, energy expenditure, and longevity</article-title>
<source/>Cell Metab.
          <year>2012</year>
<volume>15</volume>
<fpage>382</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2012.02.001</pub-id>
<pub-id pub-id-type="pmid">22405073</pub-id>
</element-citation>
</ref>
<ref id="B107-cancers-11-01247">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimobayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M.N.</given-names>
</name>
</person-group>
<article-title>Making new contacts: The mTOR network in metabolism and signalling crosstalk</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2014</year>
<volume>15</volume>
<fpage>155</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3757</pub-id>
<pub-id pub-id-type="pmid">24556838</pub-id>
</element-citation>
</ref>
<ref id="B108-cancers-11-01247">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Peacock</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Yau</surname>
<given-names>T.Y.</given-names>
</name>
<name>
<surname>Mui</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Sossi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Doudet</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ruth</surname>
<given-names>T.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity</article-title>
<source/>Diabetologia
          <year>2007</year>
<volume>50</volume>
<fpage>395</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-006-0531-x</pub-id>
<pub-id pub-id-type="pmid">17195063</pub-id>
</element-citation>
</ref>
<ref id="B109-cancers-11-01247">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miinea</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peranen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Lienhard</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain</article-title>
<source/>Biochem. J.
          <year>2005</year>
<volume>391</volume>
<fpage>87</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20050887</pub-id>
<pub-id pub-id-type="pmid">15971998</pub-id>
</element-citation>
</ref>
<ref id="B110-cancers-11-01247">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dallas-Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Castriota</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of a novel GLUT4 translocation assay for identifying potential novel therapeutic targets for insulin sensitization</article-title>
<source/>Biochem. J.
          <year>2009</year>
<volume>418</volume>
<fpage>413</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20082051</pub-id>
<pub-id pub-id-type="pmid">19035854</pub-id>
</element-citation>
</ref>
<ref id="B111-cancers-11-01247">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puigserver</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rhee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Walkey</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Oriente</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Altomonte</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Accili</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1 alpha interaction</article-title>
<source/>Nature
          <year>2003</year>
<volume>423</volume>
<fpage>550</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1038/nature01667</pub-id>
<pub-id pub-id-type="pmid">12754525</pub-id>
</element-citation>
</ref>
<ref id="B112-cancers-11-01247">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Monks</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Q.Y.</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1 alpha transcription coactivator</article-title>
<source/>Nature
          <year>2007</year>
<volume>447</volume>
<fpage>1012-U1018</fpage>
<pub-id pub-id-type="doi">10.1038/nature05861</pub-id>
<pub-id pub-id-type="pmid">17554339</pub-id>
</element-citation>
</ref>
<ref id="B113-cancers-11-01247">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.D.</given-names>
</name>
</person-group>
<article-title>The ER UDPase ENTPD5 Promotes Protein N-Glycosylation, the Warburg Effect, and Proliferation in the PTEN Pathway</article-title>
<source/>Cell
          <year>2010</year>
<volume>143</volume>
<fpage>711</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2010.10.010</pub-id>
<pub-id pub-id-type="pmid">21074248</pub-id>
</element-citation>
</ref>
<ref id="B114-cancers-11-01247">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Sampieri</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clohessy</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Mendez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gonzalez-Billalabeitia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Katon</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer</article-title>
<source/>Nat. Genet.
          <year>2018</year>
<volume>50</volume>
<fpage>206</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1038/s41588-017-0027-2</pub-id>
<pub-id pub-id-type="pmid">29335545</pub-id>
</element-citation>
</ref>
<ref id="B115-cancers-11-01247">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoncu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Efeyan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>mTOR: From growth signal integration to cancer, diabetes and ageing</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2011</year>
<volume>12</volume>
<fpage>21</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3025</pub-id>
<pub-id pub-id-type="pmid">21157483</pub-id>
</element-citation>
</ref>
<ref id="B116-cancers-11-01247">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zabala-Letona</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arruabarrena-Aristorena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martin-Martin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fernandez-Ruiz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Clasquin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tomas-Cortazar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Quang</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer</article-title>
<source/>Nature
          <year>2017</year>
<volume>547</volume>
<fpage>109</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1038/nature22964</pub-id>
<pub-id pub-id-type="pmid">28658205</pub-id>
</element-citation>
</ref>
<ref id="B117-cancers-11-01247">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Cao</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Hobbs</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>V.C.J.</given-names>
</name>
<name>
<surname>Anastasiou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Rameh</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State</article-title>
<source/>Cell
          <year>2012</year>
<volume>149</volume>
<fpage>49</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.02.030</pub-id>
<pub-id pub-id-type="pmid">22401813</pub-id>
</element-citation>
</ref>
<ref id="B118-cancers-11-01247">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tosoian</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Almutairi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Morais</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Glavaris</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sundi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Humphreys</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Marzo</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>A.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy</article-title>
<source/>Eur. Urol.
          <year>2017</year>
<volume>71</volume>
<fpage>697</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="doi">10.1016/j.eururo.2016.07.026</pub-id>
<pub-id pub-id-type="pmid">27477529</pub-id>
</element-citation>
</ref>
<ref id="B119-cancers-11-01247">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Zan</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.L.</given-names>
</name>
</person-group>
<article-title>High-expression of DJ-1 and Loss of PTEN Associated with Tumor Metastasis and Correlated with Poor Prognosis of Gastric Carcinoma</article-title>
<source/>Int. J. Med. Sci.
          <year>2013</year>
<volume>10</volume>
<fpage>1689</fpage>
<lpage>1697</lpage>
<pub-id pub-id-type="doi">10.7150/ijms.7292</pub-id>
<pub-id pub-id-type="pmid">24155657</pub-id>
</element-citation>
</ref>
<ref id="B120-cancers-11-01247">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Lonigro</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Vats</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cobain</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Everett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Rabban</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kumar-Sinha</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrative clinical genomics of metastatic cancer</article-title>
<source/>Nature
          <year>2017</year>
<volume>548</volume>
<fpage>297</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1038/nature23306</pub-id>
<pub-id pub-id-type="pmid">28783718</pub-id>
</element-citation>
</ref>
<ref id="B121-cancers-11-01247">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Q.Y.</given-names>
</name>
<name>
<surname>Rozengurt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pritchard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Roy-Burman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>P.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer</article-title>
<source/>Cancer Cell
          <year>2003</year>
<volume>4</volume>
<fpage>209</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1016/S1535-6108(03)00215-0</pub-id>
<pub-id pub-id-type="pmid">14522255</pub-id>
</element-citation>
</ref>
<ref id="B122-cancers-11-01247">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulholland</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ruscetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Gleave</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells</article-title>
<source/>Cancer Res.
          <year>2012</year>
<volume>72</volume>
<fpage>1878</fpage>
<lpage>1889</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3132</pub-id>
<pub-id pub-id-type="pmid">22350410</pub-id>
</element-citation>
</ref>
<ref id="B123-cancers-11-01247">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogueira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Paraiso</surname>
<given-names>K.H.T.</given-names>
</name>
<name>
<surname>Dannenberg</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Bosenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis</article-title>
<source/>Oncogene
          <year>2010</year>
<volume>29</volume>
<fpage>6222</fpage>
<lpage>6232</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2010.349</pub-id>
<pub-id pub-id-type="pmid">20711233</pub-id>
</element-citation>
</ref>
<ref id="B124-cancers-11-01247">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.Y.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis</article-title>
<source/>J. Clin. Investig.
          <year>2017</year>
<volume>127</volume>
<fpage>1284</fpage>
<lpage>1302</lpage>
<pub-id pub-id-type="doi">10.1172/JCI91144</pub-id>
<pub-id pub-id-type="pmid">28319045</pub-id>
</element-citation>
</ref>
<ref id="B125-cancers-11-01247">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Won</surname>
<given-names>O.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Q.T.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.H.F.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Paulter</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Creighton</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Ittmann</surname>
<given-names>M.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model</article-title>
<source/>J. Clin. Investig.
          <year>2016</year>
<volume>126</volume>
<fpage>2626</fpage>
<lpage>2641</lpage>
<pub-id pub-id-type="doi">10.1172/Jci84637</pub-id>
<pub-id pub-id-type="pmid">27294523</pub-id>
</element-citation>
</ref>
<ref id="B126-cancers-11-01247">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dankort</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Curley</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Cartlidge</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karnezis</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Damsky</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>DePinho</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bosenberg</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Braf(V600E) cooperates with Pten loss to induce metastatic melanoma</article-title>
<source/>Nat. Genet.
          <year>2009</year>
<volume>41</volume>
<fpage>544</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.1038/ng.356</pub-id>
<pub-id pub-id-type="pmid">19282848</pub-id>
</element-citation>
</ref>
<ref id="B127-cancers-11-01247">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>Z.H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Labrot</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Lis</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression</article-title>
<source/>Nature
          <year>2011</year>
<volume>470</volume>
<fpage>269</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1038/nature09677</pub-id>
<pub-id pub-id-type="pmid">21289624</pub-id>
</element-citation>
</ref>
<ref id="B128-cancers-11-01247">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liliental</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Lesche</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mamillapalli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases</article-title>
<source/>Curr. Biol.
          <year>2000</year>
<volume>10</volume>
<fpage>401</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1016/S0960-9822(00)00417-6</pub-id>
<pub-id pub-id-type="pmid">10753747</pub-id>
</element-citation>
</ref>
<ref id="B129-cancers-11-01247">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raftopoulou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Etienne-Manneville</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Self</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nicholls</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Regulation of cell migration by the C2 domain of the tumor suppressor PTEN</article-title>
<source/>Science
          <year>2004</year>
<volume>303</volume>
<fpage>1179</fpage>
<lpage>1181</lpage>
<pub-id pub-id-type="doi">10.1126/science.1092089</pub-id>
<pub-id pub-id-type="pmid">14976311</pub-id>
</element-citation>
</ref>
<ref id="B130-cancers-11-01247">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.S.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Weijer</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>PtdIns(3,4,5)P-3-dependent and -independent roles for PTEN in the control of cell migration</article-title>
<source/>Curr. Biol.
          <year>2007</year>
<volume>17</volume>
<fpage>115</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2006.12.026</pub-id>
<pub-id pub-id-type="pmid">17240336</pub-id>
</element-citation>
</ref>
<ref id="B131-cancers-11-01247">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma</article-title>
<source/>Cancer Gene Ther.
          <year>2015</year>
<volume>22</volume>
<fpage>351</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1038/cgt.2015.27</pub-id>
<pub-id pub-id-type="pmid">26160225</pub-id>
</element-citation>
</ref>
<ref id="B132-cancers-11-01247">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmeliet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Angiogenesis in cancer and other diseases</article-title>
<source/>Nature
          <year>2000</year>
<volume>407</volume>
<fpage>249</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1038/35025220</pub-id>
<pub-id pub-id-type="pmid">11001068</pub-id>
</element-citation>
</ref>
<ref id="B133-cancers-11-01247">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stolarov</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Wigler</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Tonks</surname>
<given-names>N.K.</given-names>
</name>
<name>
<surname>Durden</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>PTEN controls tumor-induced angiogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>4622</fpage>
<lpage>4627</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.081063798</pub-id>
<pub-id pub-id-type="pmid">11274365</pub-id>
</element-citation>
</ref>
<ref id="B134-cancers-11-01247">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choorapoikayil</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weijts</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de Bruin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>den Hertog</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Loss of Pten promotes angiogenesis and enhanced vegfaa expression in zebrafish</article-title>
<source/>Dis. Models Mech.
          <year>2013</year>
<volume>6</volume>
<fpage>1159</fpage>
<lpage>1166</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.012377</pub-id>
</element-citation>
</ref>
<ref id="B135-cancers-11-01247">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nan</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.A.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>Z.P.</given-names>
</name>
</person-group>
<article-title>PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells</article-title>
<source/>Carcinogenesis
          <year>2010</year>
<volume>31</volume>
<fpage>1211</fpage>
<lpage>1219</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgq085</pub-id>
<pub-id pub-id-type="pmid">20430845</pub-id>
</element-citation>
</ref>
<ref id="B136-cancers-11-01247">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serra</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chivite</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Angulo-Urarte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Arruabarrena-Aristorena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ragab</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Malumbres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fruttiger</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN mediates Notch-dependent stalk cell arrest in angiogenesis</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>7935</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms8935</pub-id>
<pub-id pub-id-type="pmid">26228240</pub-id>
</element-citation>
</ref>
<ref id="B137-cancers-11-01247">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Henson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wehbe-Janek</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ghoshal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer</article-title>
<source/>Gastroenterology
          <year>2007</year>
<volume>133</volume>
<fpage>647</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2007.05.022</pub-id>
<pub-id pub-id-type="pmid">17681183</pub-id>
</element-citation>
</ref>
<ref id="B138-cancers-11-01247">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huse</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hambardzumyan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pena</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rouhanifard</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Sohn-Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>le Sage</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Agami</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tuschl</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo</article-title>
<source/>Genes Dev.
          <year>2009</year>
<volume>23</volume>
<fpage>1327</fpage>
<lpage>1337</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1777409</pub-id>
<pub-id pub-id-type="pmid">19487573</pub-id>
</element-citation>
</ref>
<ref id="B139-cancers-11-01247">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>MicroRNA-92a promotes metastasis of nasopharyngeal carcinoma by targeting the PTEN/AKT pathway</article-title>
<source/>Onco Targets Ther.
          <year>2016</year>
<volume>9</volume>
<fpage>3579</fpage>
<lpage>3588</lpage>
<pub-id pub-id-type="doi">10.2147/OTT.S105470</pub-id>
<pub-id pub-id-type="pmid">27366095</pub-id>
</element-citation>
</ref>
<ref id="B140-cancers-11-01247">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bahr</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zanesi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Croce</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>miR-130a Deregulates PTEN and Stimulates Tumor Growth</article-title>
<source/>Cancer Res.
          <year>2017</year>
<volume>77</volume>
<fpage>6168</fpage>
<lpage>6178</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0530</pub-id>
<pub-id pub-id-type="pmid">28935812</pub-id>
</element-citation>
</ref>
<ref id="B141-cancers-11-01247">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells</article-title>
<source/>Gene
          <year>2019</year>
<volume>710</volume>
<fpage>103</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2019.05.058</pub-id>
<pub-id pub-id-type="pmid">31158447</pub-id>
</element-citation>
</ref>
<ref id="B142-cancers-11-01247">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1beta induction</article-title>
<source/>Mol. Cancer
          <year>2014</year>
<volume>13</volume>
<fpage>40</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-13-40</pub-id>
<pub-id pub-id-type="pmid">24571667</pub-id>
</element-citation>
</ref>
<ref id="B143-cancers-11-01247">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poliseno</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Salmena</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carver</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haveman</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>A coding-independent function of gene and pseudogene mRNAs regulates tumour biology</article-title>
<source/>Nature
          <year>2010</year>
<volume>465</volume>
<fpage>1033</fpage>
<lpage>1038</lpage>
<pub-id pub-id-type="doi">10.1038/nature09144</pub-id>
<pub-id pub-id-type="pmid">20577206</pub-id>
</element-citation>
</ref>
<ref id="B144-cancers-11-01247">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Overexpression of lncRNA PTENP1 suppresses glioma cell proliferation and metastasis in vitro</article-title>
<source/>Onco Targets Ther.
          <year>2019</year>
<volume>12</volume>
<fpage>147</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.2147/OTT.S182537</pub-id>
<pub-id pub-id-type="pmid">30613153</pub-id>
</element-citation>
</ref>
<ref id="B145-cancers-11-01247">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Overexpression of Long Noncoding RNA PTENP1 Inhibits Cell Proliferation and Migration via Suppression of miR-19b in Breast Cancer Cells</article-title>
<source/>Oncol. Res.
          <year>2018</year>
<volume>26</volume>
<fpage>869</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.3727/096504017X15123838050075</pub-id>
<pub-id pub-id-type="pmid">29212574</pub-id>
</element-citation>
</ref>
<ref id="B146-cancers-11-01247">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression</article-title>
<source/>Mol. Cancer
          <year>2018</year>
<volume>17</volume>
<fpage>143</fpage>
<pub-id pub-id-type="doi">10.1186/s12943-018-0880-3</pub-id>
<pub-id pub-id-type="pmid">30285771</pub-id>
</element-citation>
</ref>
<ref id="B147-cancers-11-01247">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McConnachie</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pass</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>C.P.</given-names>
</name>
</person-group>
<article-title>Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: Evidence for activation by anionic phospholipids</article-title>
<source/>Biochem. J.
          <year>2003</year>
<volume>371</volume>
<fpage>947</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1042/bj20021848</pub-id>
<pub-id pub-id-type="pmid">12534371</pub-id>
</element-citation>
</ref>
<ref id="B148-cancers-11-01247">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redfern</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Redfern</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Furgason</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Munson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Gericke</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>PTEN phosphatase selectively binds phosphoinositides and undergoes structural changes</article-title>
<source/>Biochemistry
          <year>2008</year>
<volume>47</volume>
<fpage>2162</fpage>
<lpage>2171</lpage>
<pub-id pub-id-type="doi">10.1021/bi702114w</pub-id>
<pub-id pub-id-type="pmid">18220422</pub-id>
</element-citation>
</ref>
<ref id="B149-cancers-11-01247">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Panuzzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crivellaro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carra</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fava</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guerrasio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Saglio</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation</article-title>
<source/>Cell Cycle
          <year>2015</year>
<volume>14</volume>
<fpage>973</fpage>
<lpage>979</lpage>
<pub-id pub-id-type="doi">10.1080/15384101.2015.1006970</pub-id>
<pub-id pub-id-type="pmid">25608112</pub-id>
</element-citation>
</ref>
<ref id="B150-cancers-11-01247">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chaffotte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Terrien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Prehaud</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Theillet</surname>
<given-names>F.X.</given-names>
</name>
<name>
<surname>Delepierre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lafon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buc</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Ordered phosphorylation events in two independent cascades of the PTEN C-tail revealed by NMR</article-title>
<source/>J. Am. Chem. Soc.
          <year>2012</year>
<volume>134</volume>
<fpage>20533</fpage>
<lpage>20543</lpage>
<pub-id pub-id-type="doi">10.1021/ja310214g</pub-id>
<pub-id pub-id-type="pmid">23171049</pub-id>
</element-citation>
</ref>
<ref id="B151-cancers-11-01247">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odriozola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hoang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain</article-title>
<source/>J. Biol. Chem.
          <year>2007</year>
<volume>282</volume>
<fpage>23306</fpage>
<lpage>23315</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M611240200</pub-id>
<pub-id pub-id-type="pmid">17565999</pub-id>
</element-citation>
</ref>
<ref id="B152-cancers-11-01247">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahdar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Devreotes</surname>
<given-names>P.N.</given-names>
</name>
</person-group>
<article-title>A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>480</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0811212106</pub-id>
<pub-id pub-id-type="pmid">19114656</pub-id>
</element-citation>
</ref>
<ref id="B153-cancers-11-01247">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Kriplani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hermida</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Alvarez-Garcia</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Wise</surname>
<given-names>H.M.</given-names>
</name>
</person-group>
<article-title>The PTEN protein: Cellular localization and post-translational regulation</article-title>
<source/>Biochem. Soc. Trans.
          <year>2016</year>
<volume>44</volume>
<fpage>273</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1042/BST20150224</pub-id>
<pub-id pub-id-type="pmid">26862215</pub-id>
</element-citation>
</ref>
<ref id="B154-cancers-11-01247">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Afkari</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Senoo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sesaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Devreotes</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium</article-title>
<source/>Oncogene
          <year>2014</year>
<volume>33</volume>
<fpage>5688</fpage>
<lpage>5696</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2013.507</pub-id>
<pub-id pub-id-type="pmid">24292679</pub-id>
</element-citation>
</ref>
<ref id="B155-cancers-11-01247">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Afkari</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Sesaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Devreotes</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2014</year>
<volume>111</volume>
<fpage>E2684</fpage>
<lpage>E2693</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1409433111</pub-id>
<pub-id pub-id-type="pmid">24979808</pub-id>
</element-citation>
</ref>
<ref id="B156-cancers-11-01247">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rhee</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Reversible inactivation of the tumor suppressor PTEN by H2O2</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>20336</fpage>
<lpage>20342</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111899200</pub-id>
<pub-id pub-id-type="pmid">11916965</pub-id>
</element-citation>
</ref>
<ref id="B157-cancers-11-01247">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Stadtman</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Rhee</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2004</year>
<volume>101</volume>
<fpage>16419</fpage>
<lpage>16424</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0407396101</pub-id>
<pub-id pub-id-type="pmid">15534200</pub-id>
</element-citation>
</ref>
<ref id="B158-cancers-11-01247">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwertassek</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Haque</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Weingarten</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Tonks</surname>
<given-names>N.K.</given-names>
</name>
</person-group>
<article-title>Reactivation of oxidized PTP1B and PTEN by thioredoxin 1</article-title>
<source/>FEBS J.
          <year>2014</year>
<volume>281</volume>
<fpage>3545</fpage>
<lpage>3558</lpage>
<pub-id pub-id-type="doi">10.1111/febs.12898</pub-id>
<pub-id pub-id-type="pmid">24976139</pub-id>
</element-citation>
</ref>
<ref id="B159-cancers-11-01247">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chay</surname>
<given-names>K.O.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Redox regulation of the tumor suppressor PTEN by the thioredoxin system and cumene hydroperoxide</article-title>
<source/>Free Radic. Biol. Med.
          <year>2017</year>
<volume>112</volume>
<fpage>277</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.07.029</pub-id>
<pub-id pub-id-type="pmid">28774816</pub-id>
</element-citation>
</ref>
<ref id="B160-cancers-11-01247">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T.Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Chay</surname>
<given-names>K.O.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Redox regulation of the tumor suppressor PTEN by glutathione</article-title>
<source/>FEBS Lett.
          <year>2010</year>
<volume>584</volume>
<fpage>3550</fpage>
<lpage>3556</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2010.07.006</pub-id>
<pub-id pub-id-type="pmid">20637195</pub-id>
</element-citation>
</ref>
<ref id="B161-cancers-11-01247">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chay</surname>
<given-names>K.O.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Redox Regulation of the Tumor Suppressor PTEN by Hydrogen Peroxide and Tert-Butyl Hydroperoxide</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<elocation-id>18</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19010018</pub-id>
</element-citation>
</ref>
<ref id="B162-cancers-11-01247">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation</article-title>
<source/>Cell Res.
          <year>2013</year>
<volume>23</volume>
<fpage>552</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2013.27</pub-id>
<pub-id pub-id-type="pmid">23419514</pub-id>
</element-citation>
</ref>
<ref id="B163-cancers-11-01247">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naguib</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bencze</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tocilj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Elkayam</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Faehnle</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Jaber</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN functions by recruitment to cytoplasmic vesicles</article-title>
<source/>Mol. Cell
          <year>2015</year>
<volume>58</volume>
<fpage>255</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2015.03.011</pub-id>
<pub-id pub-id-type="pmid">25866245</pub-id>
</element-citation>
</ref>
<ref id="B164-cancers-11-01247">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fotin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grigorieff</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Walz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Kirchhausen</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Structure of an auxilin-bound clathrin coat and its implications for the mechanism of uncoating</article-title>
<source/>Nature
          <year>2004</year>
<volume>432</volume>
<fpage>649</fpage>
<lpage>653</lpage>
<pub-id pub-id-type="doi">10.1038/nature03078</pub-id>
<pub-id pub-id-type="pmid">15502813</pub-id>
</element-citation>
</ref>
<ref id="B165-cancers-11-01247">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shenoy</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Nanda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Losche</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Membrane association of the PTEN tumor suppressor: Electrostatic interaction with phosphatidylserine-containing bilayers and regulatory role of the C-terminal tail</article-title>
<source/>J. Struct. Biol.
          <year>2012</year>
<volume>180</volume>
<fpage>394</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsb.2012.10.003</pub-id>
<pub-id pub-id-type="pmid">23073177</pub-id>
</element-citation>
</ref>
<ref id="B166-cancers-11-01247">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dempsey</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bolduc</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Molecular Features of Phosphatase and Tensin Homolog (PTEN) Regulation by C-terminal Phosphorylation</article-title>
<source/>J. Biol. Chem.
          <year>2016</year>
<volume>291</volume>
<fpage>14160</fpage>
<lpage>14169</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M116.728980</pub-id>
<pub-id pub-id-type="pmid">27226612</pub-id>
</element-citation>
</ref>
<ref id="B167-cancers-11-01247">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>PTEN hopping on the cell membrane is regulated via a positively-charged C2 domain</article-title>
<source/>PLoS Comput. Biol.
          <year>2014</year>
<volume>10</volume>
<elocation-id>e1003817</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1003817</pub-id>
<pub-id pub-id-type="pmid">25211206</pub-id>
</element-citation>
</ref>
<ref id="B168-cancers-11-01247">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masson</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Perisic</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity</article-title>
<source/>Biochem. J.
          <year>2016</year>
<volume>473</volume>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20150931</pub-id>
<pub-id pub-id-type="pmid">26527737</pub-id>
</element-citation>
</ref>
<ref id="B169-cancers-11-01247">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Eickholt</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes</article-title>
<source/>J. Med. Genet.
          <year>2015</year>
<volume>52</volume>
<fpage>128</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102803</pub-id>
<pub-id pub-id-type="pmid">25527629</pub-id>
</element-citation>
</ref>
<ref id="B170-cancers-11-01247">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lamb</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>PTEN C-terminal deletion causes genomic instability and tumor development</article-title>
<source/>Cell Rep.
          <year>2014</year>
<volume>6</volume>
<fpage>844</fpage>
<lpage>854</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2014.01.030</pub-id>
<pub-id pub-id-type="pmid">24561254</pub-id>
</element-citation>
</ref>
<ref id="B171-cancers-11-01247">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Koppie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Alimonti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Erdjument-Bromage</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tempst</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cordon-Cardo</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN</article-title>
<source/>Cell
          <year>2007</year>
<volume>128</volume>
<fpage>129</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.11.039</pub-id>
<pub-id pub-id-type="pmid">17218260</pub-id>
</element-citation>
</ref>
<ref id="B172-cancers-11-01247">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correia</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Girio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Antunes</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Barata</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>The multiple layers of non-genetic regulation of PTEN tumour suppressor activity</article-title>
<source/>Eur. J. Cancer
          <year>2014</year>
<volume>50</volume>
<fpage>216</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejca.2013.08.017</pub-id>
<pub-id pub-id-type="pmid">24054978</pub-id>
</element-citation>
</ref>
<ref id="B173-cancers-11-01247">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>Y.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN</article-title>
<source/>Cell Death Differ.
          <year>2014</year>
<volume>21</volume>
<fpage>146</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2013.141</pub-id>
<pub-id pub-id-type="pmid">24141722</pub-id>
</element-citation>
</ref>
<ref id="B174-cancers-11-01247">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Levy-Cohen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Blank</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Molecular functions of NEDD4 E3 ubiquitin ligases in cancer</article-title>
<source/>Biochim. Biophys. Acta
          <year>2015</year>
<volume>1856</volume>
<fpage>91</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbcan.2015.06.005</pub-id>
<pub-id pub-id-type="pmid">26116757</pub-id>
</element-citation>
</ref>
<ref id="B175-cancers-11-01247">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CK1alpha suppresses lung tumour growth by stabilizing PTEN and inducing autophagy</article-title>
<source/>Nat. Cell Biol.
          <year>2018</year>
<volume>20</volume>
<fpage>465</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="doi">10.1038/s41556-018-0065-8</pub-id>
<pub-id pub-id-type="pmid">29593330</pub-id>
</element-citation>
</ref>
<ref id="B176-cancers-11-01247">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Eide</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Eilertsen</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Danielsen</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Eknaes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hektoen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lind</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Lothe</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Epigenetic and genetic features of 24 colon cancer cell lines</article-title>
<source/>Oncogenesis
          <year>2013</year>
<volume>2</volume>
<fpage>e71</fpage>
<pub-id pub-id-type="doi">10.1038/oncsis.2013.35</pub-id>
<pub-id pub-id-type="pmid">24042735</pub-id>
</element-citation>
</ref>
<ref id="B177-cancers-11-01247">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maddika</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kavela</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Palicharla</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Pokorny</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Sarkaria</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>WWP2 is an E3 ubiquitin ligase for PTEN</article-title>
<source/>Nat. Cell Biol.
          <year>2011</year>
<volume>13</volume>
<fpage>728</fpage>
<lpage>733</lpage>
<pub-id pub-id-type="doi">10.1038/ncb2240</pub-id>
<pub-id pub-id-type="pmid">21532586</pub-id>
</element-citation>
</ref>
<ref id="B178-cancers-11-01247">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hacker</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lenna</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jimenez-Cervantes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.X.</given-names>
</name>
<name>
<surname>Widlund</surname>
<given-names>H.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MC1R is a potent regulator of PTEN after UV exposure in melanocytes</article-title>
<source/>Mol. Cell
          <year>2013</year>
<volume>51</volume>
<fpage>409</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2013.08.010</pub-id>
<pub-id pub-id-type="pmid">23973372</pub-id>
</element-citation>
</ref>
<ref id="B179-cancers-11-01247">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clements</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Koivisto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>WWP2 and its association with PTEN in endometrial cancer</article-title>
<source/>Gynecol. Oncol. Rep.
          <year>2015</year>
<volume>13</volume>
<fpage>26</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.gore.2015.05.004</pub-id>
<pub-id pub-id-type="pmid">26425715</pub-id>
</element-citation>
</ref>
<ref id="B180-cancers-11-01247">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Malumbres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner</article-title>
<source/>Cell Discov.
          <year>2016</year>
<volume>2</volume>
<fpage>15044</fpage>
<pub-id pub-id-type="doi">10.1038/celldisc.2015.44</pub-id>
<pub-id pub-id-type="pmid">27462441</pub-id>
</element-citation>
</ref>
<ref id="B181-cancers-11-01247">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>WWP2 is a physiological ubiquitin ligase for phosphatase and tensin homolog (PTEN) in mice</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>8886</fpage>
<lpage>8899</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA117.001060</pub-id>
<pub-id pub-id-type="pmid">29685889</pub-id>
</element-citation>
</ref>
<ref id="B182-cancers-11-01247">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Bertoli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grimal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mansat-De Mas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dozier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tamburini</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Recher</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Didier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Manenti</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia</article-title>
<source/>Leukemia
          <year>2014</year>
<volume>28</volume>
<fpage>293</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2013.168</pub-id>
<pub-id pub-id-type="pmid">23748345</pub-id>
</element-citation>
</ref>
<ref id="B183-cancers-11-01247">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Setijono</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Billalabeitia</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression</article-title>
<source/>Nat. Commun.
          <year>2019</year>
<volume>10</volume>
<fpage>636</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-019-08481-x</pub-id>
<pub-id pub-id-type="pmid">30733438</pub-id>
</element-citation>
</ref>
<ref id="B184-cancers-11-01247">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watt</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Walpole</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Bulman Page</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Hemmings</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Angulo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chantry</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors</article-title>
<source/>Chemistry
          <year>2018</year>
<volume>24</volume>
<fpage>17677</fpage>
<lpage>17680</lpage>
<pub-id pub-id-type="doi">10.1002/chem.201804169</pub-id>
<pub-id pub-id-type="pmid">30207403</pub-id>
</element-citation>
</ref>
<ref id="B185-cancers-11-01247">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>J.X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Diosgenin inhibits the expression of NEDD4 in prostate cancer cells</article-title>
<source/>Am. J. Transl. Res.
          <year>2019</year>
<volume>11</volume>
<fpage>3461</fpage>
<lpage>3471</lpage>
<pub-id pub-id-type="pmid">31312358</pub-id>
</element-citation>
</ref>
<ref id="B186-cancers-11-01247">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Katon</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway</article-title>
<source/>Science
          <year>2019</year>
<volume>364</volume>
<pub-id pub-id-type="doi">10.1126/science.aau0159</pub-id>
</element-citation>
</ref>
<ref id="B187-cancers-11-01247">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Longy</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inherited PTEN mutations and the prediction of phenotype</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2016</year>
<volume>52</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2016.01.030</pub-id>
<pub-id pub-id-type="pmid">26827793</pub-id>
</element-citation>
</ref>
<ref id="B188-cancers-11-01247">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Andres-Pons</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Valiente</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cervera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pulido</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs</article-title>
<source/>Mol. Biol. Cell
          <year>2006</year>
<volume>17</volume>
<fpage>4002</fpage>
<lpage>4013</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e06-05-0380</pub-id>
<pub-id pub-id-type="pmid">16807353</pub-id>
</element-citation>
</ref>
<ref id="B189-cancers-11-01247">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Themsche</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leblanc</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Parent</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Asselin</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization</article-title>
<source/>J. Biol. Chem.
          <year>2009</year>
<volume>284</volume>
<fpage>20462</fpage>
<lpage>20466</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.C109.009522</pub-id>
<pub-id pub-id-type="pmid">19473982</pub-id>
</element-citation>
</ref>
<ref id="B190-cancers-11-01247">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>PIASxalpha ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>3217</fpage>
<lpage>3230</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.508515</pub-id>
<pub-id pub-id-type="pmid">24344134</pub-id>
</element-citation>
</ref>
<ref id="B191-cancers-11-01247">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Salmena</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carracedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Egia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lo-Coco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Teruya-Feldstein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<fpage>813</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="doi">10.1038/nature07290</pub-id>
<pub-id pub-id-type="pmid">18716620</pub-id>
</element-citation>
</ref>
<ref id="B192-cancers-11-01247">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minaguchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Waite</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein</article-title>
<source/>Cancer Res.
          <year>2006</year>
<volume>66</volume>
<fpage>11677</fpage>
<lpage>11682</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2240</pub-id>
<pub-id pub-id-type="pmid">17178862</pub-id>
</element-citation>
</ref>
<ref id="B193-cancers-11-01247">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Neo</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Gunaratne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Poulsen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boping</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Sangthongpitag</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pendharkar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Feedback regulation on PTEN/AKT pathway by the ER stress kinase PERK mediated by interaction with the Vault complex</article-title>
<source/>Cell Signal.
          <year>2015</year>
<volume>27</volume>
<fpage>436</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2014.12.010</pub-id>
<pub-id pub-id-type="pmid">25530215</pub-id>
</element-citation>
</ref>
<ref id="B194-cancers-11-01247">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Narula</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Watrud</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ambrico</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Herzka</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Zeeman</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Minderer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein</article-title>
<source/>J. Cell Biol.
          <year>2017</year>
<volume>216</volume>
<fpage>641</fpage>
<lpage>656</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201604025</pub-id>
<pub-id pub-id-type="pmid">28193700</pub-id>
</element-citation>
</ref>
<ref id="B195-cancers-11-01247">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howitt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lackovic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Naguib</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Macintyre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia</article-title>
<source/>J. Cell Biol.
          <year>2012</year>
<volume>196</volume>
<fpage>29</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201105009</pub-id>
<pub-id pub-id-type="pmid">22213801</pub-id>
</element-citation>
</ref>
<ref id="B196-cancers-11-01247">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Grb2 binds to PTEN and regulates its nuclear translocation to maintain the genomic stability in DNA damage response</article-title>
<source/>Cell Death Dis.
          <year>2019</year>
<volume>10</volume>
<fpage>546</fpage>
<pub-id pub-id-type="doi">10.1038/s41419-019-1762-3</pub-id>
<pub-id pub-id-type="pmid">31320611</pub-id>
</element-citation>
</ref>
<ref id="B197-cancers-11-01247">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells</article-title>
<source/>Autophagy
          <year>2015</year>
<volume>11</volume>
<fpage>239</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1080/15548627.2015.1009767</pub-id>
<pub-id pub-id-type="pmid">25701194</pub-id>
</element-citation>
</ref>
<ref id="B198-cancers-11-01247">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation</article-title>
<source/>Hum. Mol. Genet.
          <year>2015</year>
<volume>24</volume>
<fpage>142</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu425</pub-id>
<pub-id pub-id-type="pmid">25149476</pub-id>
</element-citation>
</ref>
<ref id="B199-cancers-11-01247">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Putz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Howitt</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Rab5 and Ndfip1 are involved in Pten ubiquitination and nuclear trafficking</article-title>
<source/>Traffic
          <year>2014</year>
<volume>15</volume>
<fpage>749</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.1111/tra.12175</pub-id>
<pub-id pub-id-type="pmid">24798731</pub-id>
</element-citation>
</ref>
<ref id="B200-cancers-11-01247">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavela</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shinde</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Ratheesh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viswakalyan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bashyam</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Gowrishankar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vamsy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pattnaik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sastry</surname>
<given-names>R.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PNUTS functions as a proto-oncogene by sequestering PTEN</article-title>
<source/>Cancer Res.
          <year>2013</year>
<volume>73</volume>
<fpage>205</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1394</pub-id>
<pub-id pub-id-type="pmid">23117887</pub-id>
</element-citation>
</ref>
<ref id="B201-cancers-11-01247">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gallick</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>W.K.</given-names>
</name>
</person-group>
<article-title>AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor</article-title>
<source/>Neuro Oncol.
          <year>2011</year>
<volume>13</volume>
<fpage>184</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1093/neuonc/noq163</pub-id>
<pub-id pub-id-type="pmid">21123367</pub-id>
</element-citation>
</ref>
<ref id="B202-cancers-11-01247">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Mulholland</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Valamehr</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mosessian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression</article-title>
<source/>Mol. Cell Biol.
          <year>2008</year>
<volume>28</volume>
<fpage>3281</fpage>
<lpage>3289</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00310-08</pub-id>
<pub-id pub-id-type="pmid">18332125</pub-id>
</element-citation>
</ref>
<ref id="B203-cancers-11-01247">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beckham</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marrison</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Norris</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e76593</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0076593</pub-id>
<pub-id pub-id-type="pmid">24098536</pub-id>
</element-citation>
</ref>
<ref id="B204-cancers-11-01247">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>PTEN phosphorylation and nuclear export mediate free fatty acid-induced oxidative stress</article-title>
<source/>Antioxid. Redox Signal.
          <year>2014</year>
<volume>20</volume>
<fpage>1382</fpage>
<lpage>1395</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2013.5498</pub-id>
<pub-id pub-id-type="pmid">24063548</pub-id>
</element-citation>
</ref>
<ref id="B205-cancers-11-01247">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>N.T.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Kadakia</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>DeltaNp63alpha represses nuclear translocation of PTEN by inhibition of NEDD4-1 in keratinocytes</article-title>
<source/>Arch. Derm. Res.
          <year>2013</year>
<volume>305</volume>
<fpage>733</fpage>
<lpage>739</lpage>
<pub-id pub-id-type="doi">10.1007/s00403-013-1352-7</pub-id>
<pub-id pub-id-type="pmid">23589096</pub-id>
</element-citation>
</ref>
<ref id="B206-cancers-11-01247">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Kommagani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Payal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Shamma</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Kadakia</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>DeltaNp63alpha regulates keratinocyte proliferation by controlling PTEN expression and localization</article-title>
<source/>Cell Death Differ.
          <year>2011</year>
<volume>18</volume>
<fpage>1924</fpage>
<lpage>1933</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2011.73</pub-id>
<pub-id pub-id-type="pmid">21637289</pub-id>
</element-citation>
</ref>
<ref id="B207-cancers-11-01247">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noguera</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Divona</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Catalano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ottone</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Florenzano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Faraoni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Battistini</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia</article-title>
<source/>Leukemia
          <year>2013</year>
<volume>27</volume>
<fpage>1037</fpage>
<lpage>1043</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2012.314</pub-id>
<pub-id pub-id-type="pmid">23183427</pub-id>
</element-citation>
</ref>
<ref id="B208-cancers-11-01247">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lobo</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Waite</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Planchon</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Romigh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Houghton</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>ATP modulates PTEN subcellular localization in multiple cancer cell lines</article-title>
<source/>Hum. Mol. Genet.
          <year>2008</year>
<volume>17</volume>
<fpage>2877</fpage>
<lpage>2885</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn185</pub-id>
<pub-id pub-id-type="pmid">18579579</pub-id>
</element-citation>
</ref>
<ref id="B209-cancers-11-01247">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Schiapparelli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Abbadi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amzel</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Sesaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Quinones-Hinojosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization</article-title>
<source/>Oncogene
          <year>2017</year>
<volume>36</volume>
<fpage>3673</fpage>
<lpage>3685</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2016.493</pub-id>
<pub-id pub-id-type="pmid">28263967</pub-id>
</element-citation>
</ref>
<ref id="B210-cancers-11-01247">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Panuzzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crivellaro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pergolizzi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Familiari</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Saglio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pandolfi</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP</article-title>
<source/>Leukemia
          <year>2014</year>
<volume>28</volume>
<fpage>1326</fpage>
<lpage>1333</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2013.370</pub-id>
<pub-id pub-id-type="pmid">24317448</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="cancers-11-01247-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Interacting partners of PTEN. Protein interaction network of 30 representative interaction partners of PTEN (red dot) based on experimental evidence. Data downloaded from STRING functional protein association networks database (<uri xlink:href="https://string-db.org">https://string-db.org</uri>).</p>
</caption>
<graphic xlink:href="cancers-11-01247-g001"></graphic>
</fig>
<fig id="cancers-11-01247-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Functional domains in PTEN are evolutionarily conserved. Schematic representations of the five conserved domains in the species are indicated. Numbers indicate amino acid positions. Clear box, distinct sequence; dotted line, gap.</p>
</caption>
<graphic xlink:href="cancers-11-01247-g002"></graphic>
</fig>
<fig id="cancers-11-01247-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Mutation status of key PTEN post-translational modification (PTM) sites in human cancers. Schematic representation of mutation numbers at each site of the seven different types of PTMs known to PTEN protein. Individual PTMs are identified by indicated color codes (lower panel). Data derived from COSMIC database (<uri xlink:href="https://cancer.sanger.ac.uk/cosmic">https://cancer.sanger.ac.uk/cosmic</uri>). The domain structure of PTEN is shown. CAT, catalytic.</p>
</caption>
<graphic xlink:href="cancers-11-01247-g003"></graphic>
</fig>
<fig id="cancers-11-01247-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Tissue distribution of PTEN. Schematic representation of relative PTEN expression in indicated organs and tissues. Data obtained from The Human Protein Atlas database (<uri xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</uri>).</p>
</caption>
<graphic xlink:href="cancers-11-01247-g004"></graphic>
</fig>
<fig id="cancers-11-01247-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Alteration frequency of PTEN in human cancers. (<bold>A</bold>) Alteration frequency (%) of PTEN in indicated tumor types. (<bold>B</bold>) The extent of co-occurrence of <italic>PTEN</italic> and <italic>TP53</italic> mutations in different human tumors are shown. Data obtained from cBioPortal for Cancer Genomics database (<uri xlink:href="https://www.cbioportal.org">https://www.cbioportal.org</uri>).</p>
</caption>
<graphic xlink:href="cancers-11-01247-g005"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>